The Journal of Clinical Psychiatry

Subject Index to Volume 64: January 2003 Through December 2003

Academic Highlights
Determining and Achieving Therapeutic Targets in Attention-Deficit/Hyperactivity Disorder. Mar 265–276
New Developments in Antipsychotic Therapy. Nov 1379–1390
Reducing the Risk for Suicide in Schizophrenia and Affective Disorders. Sept 1122–1129
Adherence see Compliance
Adolescents
Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23
Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169
"Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701
Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8
Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369
Psychopathology and age at onset of conduct problems in juvenile delinquents. Ruchkin, Aug 913–920
Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25
Affective Disorders
Ethnicity and diagnosis in patients with affective disorders. Strakowski, July 747–754
Reducing the Risk for Suicide in Schizophrenia and Affective Disorders [Academic Highlights]. Sept 1122–1129
Agitation
Agitation and inpatient suicide [letter]. Sharma V; Busch reply, Dec 1517–1518
Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. Brook, Suppl 19, 13–18
Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143
Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505
Treatment of agitation in bipolar disorder across the life cycle. Alderfer, Suppl 4, 3–9
Aggression
Aggression in the elderly. Brodaty, Suppl 4, 36–43
Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760
Hostility during admission interview as a short-term predictor of aggression in acute psychiatric male inpatients. Troisi, Dec 1460–1464
Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85
Management of Aggression Across the Life Cycle. Suppl 4, 1–46
Neuroreceptor mechanisms of aggression and its treatment. Swann, Suppl 4, 26–35
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Janowsky, Oct 1258–1265
Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143
Treating aggression in the psychiatric emergency service. Hughes, Suppl 4, 10–15
Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25
Alcohol
Psychometric evaluation of the Alcohol Use Disorders Identification Test and short Drug Abuse Screening Test with psychiatric patients in India. Carey KB, July 767–774
Two cases of alcohol craving curbed by topiramate [letter]. Komanduri, May 612
Use of antidepressants in alcohol-dependent veterans. Petrakis, Aug 865–870
Algorithms
Computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Oquendo, July 825–833
Role of algorithms in the detection and treatment of depression in primary care. Klinkman, Suppl 2, 19–23
Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Suppes, Apr 370–382
Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369
Use of algorithms to treat anxiety in primary care. Culpepper, Suppl 2, 30–33
Using treatment algorithms to bring patients to remission. Trivedi, Suppl 2, 8–13
Alzheimer's Disease
Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Stahl, Apr 466–472
Current treatments for Alzheimer's disease: cholinesterase inhibitors. Doody, Suppl 9, 11–17
Diagnosis and treatment of Alzheimer's disease. Grossberg, Suppl 9, 3–6
Neuropathologic changes in Alzheimer's disease. Wenk, Suppl 9, 7–10
Noncholinergic treatment options for Alzheimer's disease. Sano, Suppl 9, 23–28
Noncholinergic Treatments for Alzheimer's Disease. Suppl 9, 1–31
Search for better noncholinergic treatment options for Alzheimer's disease. Mintzer, Suppl 9, 18–22
Amitriptyline
Amitriptyline: dual-action antidepressant? [letter] Gillman; Thase reply, Nov 1391–1392
Analgesics
Analgesic effect of antidepressants [letter]. Fishbain; Detke reply, Jan 96–97
Anger
Anger in bipolar depression [letter]. Benazzi; Koh reply, Apr 480–481
Anticonvulsants see also specific drugs
Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. Evins, Suppl 8, 9–14
Emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. Ketter, Suppl 3, 15–20
Mechanism of action of newer anticonvulsants. White, Suppl 8, 5–8
Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34
Antidepressants see also specific drugs
Analgesic effect of antidepressants [letter]. Fishbain; Detke reply, Jan 96–97
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. Labbate, Suppl 10, 11–19
Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. Ramaekers, Jan 20–29
Are antidepressants carcinogenic? a review of preclinical and clinical studies. Sternbach, Oct 1153–1162
Computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Oquendo, July 825–833
Differences in mechanism of action between current and future antidepressants. Stahl, Suppl 13, 13–17
Do antidepressants induce rapid cycling? a gender-specific association. Yildiz, July 814–818
Effectiveness of antidepressants: comparative remission rates. Thase, Suppl 2, 3–7
Evaluating antidepressant therapies: remission as the optimal outcome. Thase, Suppl 13, 18–25

How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Keitner, Sept 1091–1093
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19
Improving adherence to antidepressants: a systematic review of interventions. Vergouwen, Dec 1415–1420
Improving antidepressant adherence. Nemeroff, Suppl 18, 25–30
Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Richelson, Suppl 13, 5–12
Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants [letter]. Aga, May 609–610
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Corya, Nov 1349–1356
Managing treatment-resistant major depression. Nelson, Suppl 1, 5–12
New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
New approaches to managing psychotic depression. Schatzberg, Suppl 1, 19–23
Possible antidepressant-associated activation of mania and psychosis in the mentally retarded: four case reports [letter]. Sahay, Apr 481–482
Potential new drug delivery systems for antidepressants: an overview. Kilts, Suppl 18, 31–33
Prevalence of antidepressant-associated erectile dysfunction. Rosen, Suppl 10, 5–10
Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. Nurnberg, Suppl 10, 20–25
Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485
Use of antidepressants in alcohol-dependent veterans. Petrakis, Aug 865–870
Use of antidepressants in novel combination therapies. Shelton, Suppl 2, 14–18
Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412

Antiemetic Drugs

Ups and downs of novel antiemetic drugs, pt 1: substance P, 5-HT, and the neuropharmacology of vomiting [Brainstorms]. Stahl, May 498–499
Ups and downs of novel antiemetic drugs, pt 2: an illustration [Brainstorms]. Stahl, June 626–627

Antipsychotics see also specific drugs

Chlorpromazine equivalent doses for the newer atypical antipsychotics. Woods, June 663–667
Choice of maintenance medication for schizophrenia. Davis, Suppl 16, 24–33
Combination therapy: is clinical practice leading the way? [letter] Welch; Stahl reply, Jan 94–96
Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Ereshefsky, Suppl 16, 18–23
Conventional antipsychotic prescription in unipolar depression, 1: an audit and recommendations for practice. Wheeler Vega, May 568–574
Conventional antipsychotic prescription in unipolar depression, 2: withdrawing conventional antipsychotics in unipolar, nonpsychotic patients. Mortimer, June 668–672
Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. Tempier, June 673–679
Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Percudani, Nov 1293–1299
Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Velligan, May 524–531
Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. Jaffe, Suppl 17, 3–6
Efficacy of atypical antipsychotics in bipolar disorders. Hirschfeld, Suppl 8, 15–21
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. Opolka, June 635–639
Factors influencing compliance in schizophrenia patients. Fleischhacker, Suppl 16, 10–13
How long should patients with psychotic depression stay on the antipsychotic medication? Rothschild, Apr 390–396
Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906
New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
New approaches to managing psychotic depression. Schatzberg, Suppl 1, 19–23
New Developments in Antipsychotic Therapy [Academic Highlights]. Nov 1379–1390
Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics [letter]. Haberfellner, July 851
Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100
Overview of partial compliance. Marder, Suppl 16, 3–9
Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Taylor, Jan 30–34
Racial differences in use of antipsychotics among patients with bipolar disorder [letter]. Szarek; Fleck reply, May 614–615
Relapse and rehospitalization: comparing oral and depot antipsychotics. Schooler, Suppl 16, 14–17
Reversal of antipsychotic-associated weight gain. O'Keefe, Aug 907–912
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Atmaca, May 598–604
Similarities and differences among antipsychotics. Tamminga, Suppl 17, 7–10
Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane, Suppl 16, 34–40
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Godleski, Feb 119–122
Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485-486
Use of atypical antipsychotics in nursing homes. Liperoti, Sept 1106–1112

Anxiety

Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335
Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482
Attending to anxiety disorders in primary care. Stein, Suppl 15, 35–39
Establishment of remission criteria for anxiety disorders. Doyle, Suppl 15, 40–45
Introduction: treating depression and anxiety to remission. Schatzberg, Suppl 15, 3–4
New molecular targets for antianxiety interventions. Gorman, Suppl 3, 28–35
Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems. Kalin, Suppl 3, 41–44
Role of GABA in anxiety disorders. Lydiard, Suppl 3, 21–27
Treatment of anxiety in suicidal patients [letter]. Rich; Fawcett reply, Dec 1518–1519
Use of algorithms to treat anxiety in primary care. Culpepper, Suppl 2, 30–33

Anxiolytics

Anxiolytics: past, present, and future agents. Nemeroff, Suppl 3, 3–6
Emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. Ketter, Suppl 3, 15–20
New molecular targets for antianxiety interventions. Gorman, Suppl 3, 28–35

Aripiprazole

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Pigott, Sept 1048–1056

Attention-Deficit/Hyperactivity Disorder

Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23
Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18
Determining and Achieving Therapeutic Targets in Attention-Deficit/Hyperactivity Disorder [Academic Highlights]. Mar 265–276
Does stimulant treatment lead to substance use disorders? Faraone, Suppl 11, 9–13
Long-Term Safety of Methylphenidate in the Treatment of ADHD: Dispelling the Myths and Misconceptions About Stimulant Therapy Abuse. Suppl 11, 1–26
Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169

Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic. Dilsaver, Oct 1170–1176
Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8
Role of executive function in ADHD. Swanson, Suppl 14, 35–39

Australia

Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181

Autism

Evidence that eicosapentaenoic acid is effective in treating autism [letter]. Johnson, July 848–849
Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25

Automobile Driving

Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. Ramaekers, Jan 20–29
Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181

Baclofen

Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. Shoptaw, Dec 1440–1448

Basal Ganglia

Possible basal ganglia pathology in children with complex symptoms. Yaryura-Tobias, Dec 1495–1501

Behavior

Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
Evaluating the efficacy of habit reversal: comparison with a placebo control. Twohig, Jan 40–48
Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85
"Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701
Possible basal ganglia pathology in children with complex symptoms. Yaryura-Tobias, Dec 1495–1501

Benzodiazepines

GABA systems, benzodiazepines, and substance dependence. Malcolm, Suppl 3, 36–40

Benzodiazepine Receptors

Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems. Kalin, Suppl 3, 41–44

Binge-Eating Disorder

Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. McElroy, July 807–813

Bipolar Disorders

Achieving Success in the Management of Bipolar Disorder: Is Lithium Sufficient? Suppl 5, 1–64
Anger in bipolar depression [letter]. Benazzi; Koh reply, Apr 480–481
Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335
Bipolar disorder and schizophrenia: distinct illnesses or a continuum? Möller, Suppl 6, 23–27
Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. Keck, Dec 1426–1435
Bipolar Disorder: Origin, Recognition, and Treatment. Suppl 6, 1–28
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
Conclusions. Bipolar disorder: origin, recognition, and treatment. Rush, Suppl 6, 28
Decision tree for the treatment of bipolar disorder. Sachs, Suppl 8, 35–40
Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. Chang KD, Aug 936–942
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
Drug combinations for mania. Mondimore, Suppl 5, 25–31
Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43
Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. Birnbaum HG, Oct 1201–1209
Efficacy of atypical antipsychotics in bipolar disorders. Hirschfeld, Suppl 8, 15–21
Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. Evins, Suppl 8, 9–14
Emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. Ketter, Suppl 3, 15–20
Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118
Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. Leverich, May 506–515
Impact of bipolar disorder on a U.S. community sample. Calabrese, Apr 425–432
Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Miklowitz, Feb 182–191
Introduction. Bipolar disorder: origin, recognition, and treatment. Rush, Suppl 6, 3
Introduction: Using the newer pharmacotherapeutic agents as mood stabilizers in bipolar spectrum disorders. Chengappa, Suppl 8, 3–4
Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201
Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37
Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52
Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93
Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. Post, June 680–690
New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34
Nutritional approach to bipolar disorder [letter]. Simmons; Simpson reply, Mar 338–339
Oxcarbazepine treatment of bipolar disorder. Ghaemi, Aug 943–945
Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. Hirschfeld, Feb 161–174
Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Calabrese, Sept 1013–1024
Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Hartong, Feb 144–151
Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. Colom, Sept 1101–1105
Racial differences in use of antipsychotics among patients with bipolar disorder [letter]. Szarek; Fleck reply, May 614–615
Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. Kupka, Dec 1483–1494
Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24
Relationship between postpartum psychosis and bipolar disorder: a review. Chaudron, Nov 1284–1292
Response, remission, and recovery in bipolar disorder: what are the realistic treatment goals? Sachs, Suppl 6, 18–22
Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846
Safety of available agents used to treat bipolar disorder: focus on weight gain. Nemeroff, May 532–539
Screening for bipolar disorder in the community. Hirschfeld, Jan 53–59
Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. Grof, Suppl 5, 53–61
Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Suppes, Apr 370–382
Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369

Toward an understanding of bipolar disorder and its origin. Rush, Suppl 6, 4–8
Treatment of agitation in bipolar disorder across the life cycle. Alderfer, Suppl 4, 3–9
Treatment of bipolar disorder. Möller, Suppl 6, 9–17
Underdiagnosis of bipolar II disorders in the community [letter]. Benazzi, Sept 1130–1131
Using the Newer Pharmacotherapeutic Agents as Mood Stabilizers in Bipolar Spectrum Disorders. Suppl 8, 1–40
Weight gain in the treatment of mood disorders. Aronne, Suppl 8, 22–29

Bleeding

Critical review of selective serotonin reuptake inhibitor–associated bleeding: balancing the risk of treating hepatitis C–infected patients. Weinrieb, Dec 1502–1510

Body Dysmorphic Disorder

Open-label study of citalopram in body dysmorphic disorder. Phillips, June 715–720

Bone

Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker D, July 761–766

Books Reviewed

Arciniegas DB, Beresford TP: *Neuropsychiatry: An Introductory Approach.* Rao, May 616–617
Barlow DH: *Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic, 2nd ed.* Prakash, Mar 345–346
Bennett MI: *Concise Guide to Managing Behavioral Health Care Within a Managed Care Environment.* Strain, Nov 1398
Berrios GE, Hodges JR (eds): *Memory Disorders in Psychiatric Practice.* Miller MG, June 736–737
Birren JE, Schaie KW (eds): *Handbook of the Psychology of Aging, 5th ed.* Casten, Feb 221
Chan CH, Luo JS, Kennedy RS: *Concise Guide to Computers in Clinical Psychiatry.* Kramer, Apr 487–488
Committee on Cultural Psychiatry: *Cultural Assessment in Clinical Psychiatry (GAP Report 145).* Kopelowicz, Mar 344
Csernansky JG (ed): *Schizophrenia: A New Guide for Clinicians.* Lee, Apr 489
Dickey B, Sederer LI (eds): *Improving Mental Health Care: Commitment to Quality.* Bennett, Apr 488–489
Ernst M, Rumsey JM (eds): *Functional Neuroimaging in Child Psychiatry.* Mrazek, Jan 102
Gelder M, Mayou R, Cowen P: *Shorter Oxford Textbook of Psychiatry, 4th ed.* Gershon, Jan 100–101
González FJ (ed): *HIV and Depression: Context and Care (UCSF AIDS Health Project Monograph Series, No. 5).* Hargrave, Feb 221–222
Gotlib IH, Hammen CL (eds): *Handbook of Depression.* Schnaas, Dec 1523–1524
Griez EJL, Faravelli C, Nutt D, Zohar J (eds): *Anxiety Disorders: An Introduction to Clinical Management and Research.* Brown LL, Jan 100
Gualtieri CT: *Brain Injury and Mental Retardation: Psychopharmacology and Neuropsychiatry.* Benjamin, Dec 1522–1523
Gutheil TG, Simon RI: *Mastering Forensic Psychiatric Practice: Advanced Strategies for the Expert Witness.* Alonso, Aug 973
Helzer JE, Hudziak JJ (eds): *Defining Psychopathology in the 21st Century: DSM-V and Beyond.* Salomon, Nov 1399
Herz MI, Marder SR: *Schizophrenia: Comprehensive Treatment and Management.* Siris, Mar 345
Hodges JR (ed): *Early-Onset Dementia: A Multidisciplinary Approach.* Kirshner, Nov 1396
Hofmann SG, Tompson MC (eds): *Treating Chronic and Severe Mental Disorders: A Handbook of Empirically Supported Interventions.* Ronis, Dec 1524
Hollander E: *Concise Guide to Anxiety Disorders.* Straumanis, Nov 1396–1397
Horowitz MJ: *Treatment of Stress Response Syndromes.* Vaillant, Oct 1272–1273
Howlin P, Udwin O (eds): *Outcomes in Neurodevelopmental and Genetic Disorders.* Matthews, Sept 1136
Jacobson SA, Pies RW, Greenblatt DJ: *Handbook of Geriatric Psychopharmacology.* Wahid, Jan 101
Kaplan GB, Hammer RP Jr (eds): *Brain Circuitry and Signaling in Psychiatry: Basic Science and Clinical Implications.* Salomon, June 737
Kupfer DJ, First MB, Regier DA (eds): *A Research Agenda for DSM-IV.* McKinney, Dec 1522
Lieberman JA, Murray R (eds): *Comprehensive Care of Schizophrenia: A Textbook of Clinical Management.* Herz, Apr 490
Marangell LB, Martinez JM, Silver JM, Yudofsky SC: *Concise Guide to Psychopharmacology.* Roerig, Nov 1397–1398
Martin A, Scahill L, Charney DS, Leckman JF (eds): *Pediatric Psychopharmacology: Principles and Practice.* Sexson, Aug 974
Melmed RN: *Mind, Body, and Medicine: An Integrative Text.* Strauss, Jan 101–102
Meyers WC: *Juvenile Sexual Homicide.* Bernet, Apr 487
Mondimore FM: *Adolescent Depression: A Guide for Parents.* Slomowitz, July 855
Paris J: *Personality Disorders Over Time: Precursors, Course, and Outcome.* Lomax, Oct 1271
Peebles-Kleiger MJ: *Beginnings: The Art and Science of Planning Psychotherapy.* Nash, June 736
Phillips KA (ed): *Somatoform and Factitious Disorders.* Sudak, Jan 99–100
Robinson DJ: *Brain Calipers, 2nd ed: Descriptive Psychopathology and the Psychiatric Mental Status Examination.* Crowder, Apr 489–490
Rogers R: *Handbook of Diagnostic and Structured Interviewing.* Reus, Apr 488
Scheiber SC, Kramer TAM, Adamowski SE (eds): *Core Competencies for Psychiatric Practice: What Clinicians Need to Know (A Report of the American Board of Psychiatry and Neurology).* Weissman, Sept 1135
Shader RI (ed): *Manual of Psychiatric Therapeutics, 3rd ed.* Freeman, Oct 1272
Simon RI, Shuman DW (eds): *Retrospective Assessment of Mental States in Litigation: Predicting the Past.* Regan, Oct 1271–1272
Spinelli MG (ed): *Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill.* Caruso, Sept 1135–1136
Stahl SM: *Essential Psychopharmacology of Antipsychotics and Mood Stabilizers.* Salzman, Aug 973–974
Stein DJ, Hollander,E (eds): *American Psychiatric Publishing Textbook of Anxiety Disorders.* Appleton, May 617–618
Theorell T (ed): *Everyday Biological Stress Mechanisms.* Straumanis, Mar 344–345
Yehuda R (ed): *Treating Trauma Survivors With PTSD.* Roback, May 617

Brain

Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17
Enlargement of brain cerebrospinal fluid spaces as a predictor of poor clinical outcome in melancholia. Cardoner, June 691–697
Long-term follow-up of magnetic resonance–detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy. Obergriesser, July 775–780

Brain Imaging

Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. Weiss, Mar 235–242
Efficacy and safety of bilateral rTMS in medication-resistant depression [letter]. Cohen, May 613–614
Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. Chang, Suppl 3, 7–14

Brainstorms

Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. Stahl, July 745–746
At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. Stahl, Apr 355–356
Deconstructing psychiatric disorders, pt 1: genotypes, symptom phenotypes, and endophenotypes. Stahl, Sept 982–983
Deconstructing psychiatric disorders, pt 2: an emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist. Stahl, Oct 1145–1146
Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes. Stahl, Aug 863–864
Neurotransmission of cognition, pt 1. Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. Stahl, Jan 4–5
Neurotransmission of cognition, pt 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. Stahl, Feb 110–111
Neurotransmission of cognition, pt 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. Stahl, Mar 230–231
Symptoms and circuits, pt 1: major depressive disorder. Stahl, Nov 1282–1283

Symptoms and circuits, pt 2: anxiety disorders. Stahl, Dec 1408–1409
Ups and downs of novel antiemetic drugs, pt 1: substance P, 5-HT, and the neuropharmacology of vomiting. Stahl, May 498–499
Ups and downs of novel antiemetic drugs, pt 2: an illustration. Stahl, June 626–627

Breastfeeding

Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80
Safety of St. John's Wort (*Hypericum perforatum*) during breastfeeding. Lee A, Aug 966–968
Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412

Bulimia Nervosa

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 1: improvement in binge and purge measures. Hoopes, Nov 1335–1341
Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 2: improvement in psychiatric measures. Hedges, Dec 1449–1454

Bupropion

Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality [letter]. Chollet, Oct 1268–1269
They could have named it "bupopion" [letter]. Jefferson, July 849–850

Burning Mouth Syndrome

Burning mouth syndrome as a side effect of SSRIs [letter]. Levenson; Maina reply, Mar 336–338

Carbamazepine

Carbamazepine treatment of adverse psychiatric effects after treatment with the nonsteroidal anti-inflammatory drug piroxicam [letter]. Eser, July 852–854
Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Hartong, Feb 144–151

Carcinogenesis

Are antidepressants carcinogenic? a review of preclinical and clinical studies. Sternbach, Oct 1153–1162

Celecoxib

Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334

Charles Bonnet Syndrome

Charles Bonnet Syndrome with visual hallucinations of childhood experience: successful treatment of 1 patient with risperidone [letter]. Maeda, Sept 1131–1132

Children

Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23
Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169
Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic. Dilsaver, Oct 1170–1176
"Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701
Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8
Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16
Possible basal ganglia pathology in children with complex symptoms. Yaryura-Tobias, Dec 1495–1501
Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369
3-Year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Masi, Sept 1039–1047
Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25

Chinese

Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926

Cholesterol

Increased cholesterol levels during paroxetine administration in healthy men. Lara, Dec 1455–1459

Cholinesterase Inhibitors

Current treatments for Alzheimer's disease: cholinesterase inhibitors. Doody, Suppl 9, 11–17

Cigarette Smoking

High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. Eichhammer, Aug 951–953

Citalopram

Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. Koran, July 793–798
Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. McElroy, July 807–813
Citalopram treatment of fluoxetine-intolerant depressed patients. Calabrese, May 562–567
Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Lavretsky, Dec 1410–1414
Effectiveness of citalopram for idiopathic chronic fatigue. Hartz, Aug 927–935
Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479
Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85
Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. Benedetti, June 648–653
Open-label study of citalopram in body dysmorphic disorder. Phillips, June 715–720

Clinical Trials

How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Keitner, Sept 1091–1093

Clozapine

Clozapine and pregnancy [letter]. Mendhekar, July 850
Clozapine and venous thromboembolism: further evidence [letter]. Selten, May 609
Clozapine-induced rabbit syndrome [letter]. Sethi, Feb 219
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760
Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Taylor, Jan 30–34
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134
Successful treatment with clozapine at higher doses after clozapine-induced priapism [letter]. de Nesnera, Nov 1394–1395
Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. Sernyak, May 605–608
Ziprasidone augmentation of clozapine in 11 patients [letter]. Kaye, Feb 215–216

Cocaine

Olanzapine for cocaine cravings and relapse prevention [letter]. Sattar, Aug 969
Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201
Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. Shoptaw, Dec 1440–1448

Cognition

Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. Weiss, Mar 235–242
Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Velligan, May 524–531
Neurotransmission of cognition, pt 1. Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine [Brainstorms]. Stahl, Jan 4–5
Neurotransmission of cognition, pt 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition [Brainstorms]. Stahl, Feb 110–111
Neurotransmission of cognition, pt 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex [Brainstorms]. Stahl, Mar 230–231
Ziprasidone and cognition: the evolving story. Harvey, Suppl 19, 33–39

Cognitive Therapy

Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Kennedy, Apr 439–444

Cohen-Mansfield Agitation Inventory
Reporting changes in scores on the Cohen-Mansfield Agitation Inventory subscales [letter]. Snowdon; Ballard reply, June 732
Combination Therapy
Combination therapy: is clinical practice leading the way? [letter] Welch; Stahl reply, Jan 94–96
Drug combinations for mania. Mondimore, Suppl 5, 25–31
Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43
Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37
Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24
Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. Grof, Suppl 5, 53–61
Use of antidepressants in novel combination therapies [commentary]. Shelton, Suppl 2, 14–18
Comorbidity
Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Papakostas, Nov 1357–1361
Compliance
Factors influencing compliance in schizophrenia patients. Fleischhacker, Suppl 16, 10–13
Improving adherence to antidepressants: a systematic review of interventions. Vergouwen, Dec 1415–1420
Improving antidepressant adherence. Nemeroff, Suppl 18, 25–30
Overview of partial compliance. Marder, Suppl 16, 3–9
Partial compliance and patient consequences in schizophrenia: our patients can do better. Keith, Nov 1308–1315
Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane, Suppl 16, 34–40
Compulsive Shopping Disorder
Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. Koran, July 793–798
1-Year naturalistic follow-up of patients with compulsive shopping disorder. Aboujaoude, Aug 946–950
Conduct Disorder
Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. Steiner, Oct 1183–1191
Psychopathology and age at onset of conduct problems in juvenile delinquents. Ruchkin, Aug 913–920
Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25
Consensus Statements
Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100
Controlled-Release Technologies
At long last, long-lasting psychiatric medications: an overview of controlled-release technologies [BRAINSTORMS]. Stahl, Apr 355–356
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19
Corrections
Oral magnesium ion shortens prolonged QTc interval [letter]. Bachman, June 733–734. Correction, Aug 972
Venlafaxine in treatment-resistant obsessive-compulsive disorder. Hollander E, May 546–550. Correction, Aug 972
Costs of Medical Care see also Pharmacoeconomics
Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Endicott, Dec 1511–1516
Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Percudani, Nov 1293–1299
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
Economic and human impact of new drugs. Lichtenberg, Suppl 17, 15–18
Economic burden of depression in the United States: how did it change between 1990 and 2000? Greenberg, Dec 1465–1475
Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23
Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. Birnbaum HG, Oct 1201–1209
Limiting access to psychiatric services can increase total health care costs. Horn, Suppl 17, 23–28
Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor, May 589–597
Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill. Soumerai, Suppl 17, 19–22
Creatine Kinase
Olanzapine elevation of serum creatine kinase [letter]. Martí-Bonmatí, Apr 483–484
Delirium
Prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Sasaki, Nov 1316–1321
Dementia
Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. Brodaty, Jan 63–72
Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143
Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521
Depersonalization Disorder
Feeling unreal: a depersonalization disorder update of 117 cases. Simeon, Sept 990–997
Depression
Achieving remission and managing relapse in depression. Thase, Suppl 18, 3–7
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. DeBattista, Sept 1057–1064
Aerobic endurance exercise improves executive functions in depressed patients. Kubesch, Sept 1005–1012
Aging male: androgens, erectile dysfunction, and depression. Seidman, Suppl 10, 31–37
Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17
Can long-term treatment with antidepressant drugs worsen the course of depression? Fava GA, Feb 123–133
Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
Citalopram treatment of fluoxetine-intolerant depressed patients. Calabrese, May 562–567
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229
Computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Oquendo, July 825–833
Conventional antipsychotic prescription in unipolar depression, 1: an audit and recommendations for practice. Wheeler Vega, May 568–574
Conventional antipsychotic prescription in unipolar depression, 2: withdrawing conventional antipsychotics in unipolar, nonpsychotic patients. Mortimer, June 668–672
Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330
Depression: links with ischemic heart disease and erectile dysfunction. Roose, Suppl 10, 26–30
Depression with physical symptoms: treating to remission. Fava, Suppl 7, 24–28
Difficult-to-treat depressions: a primary care perspective. Manning, Suppl 1, 24–31
Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214
Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926

Double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Barbosa, Apr 403–407
Duloxetine in the long-term treatment of major depressive disorder. Raskin, Oct 1237–1244
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Szegedi, Apr 413–420
Economic burden of depression in the United States: how did it change between 1990 and 2000? Greenberg, Dec 1465–1475
Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23
Efficacy and safety of bilateral rTMS in medication-resistant depression [letter]. Cohen, May 613–614
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Schatzberg, Suppl 13, 30–37
Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479
Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport, Sept 1065–1074
Electroconvulsive therapy update: recognizing and treating psychotic depression [editorial]. Fink, Mar 232–234
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852
Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. Feiger, Mar 243–249
How long should patients with psychotic depression stay on the antipsychotic medication? Rothschild, Apr 390–396
How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Keitner, Sept 1091–1093
Introduction: erectile dysfunction and comorbid depression: prevalence, treatment strategies, and associated medical conditions. Nurnberg, Suppl 10, 3–4
Introduction: recent developments in achieving depression remission. Schatzberg, Suppl 13, 4
Introduction: treating depression and anxiety to remission. Schatzberg, Suppl 15, 3–4
Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Kennedy, Apr 439–444
Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37
Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52
Managing treatment-resistant major depression. Nelson, Suppl 1, 5–12
Negative symptoms in depressed and schizophrenic patients: how do they differ? Bottlender, Aug 954–958
New Approaches to Managing Difficult-to-Treat Depressions. Suppl 1, 1–34
New approaches to managing difficult-to-treat depressions. Thase, Suppl 1, 3–4
New approaches to managing psychotic depression. Schatzberg, Suppl 1, 19–23
Nortriptyline for treatment-resistant depression. Nierenberg, Jan 35–39
Open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. Carvalhal, Apr 421–424
Physical Symptoms of Depression and Their Impact on Patients and Society. Suppl 7, 1–31
Physical symptoms of depression as a public health concern. Sartorius, Suppl 7, 3–4
Physical symptoms of depression: unmet needs. Greden, Suppl 7, 5–11
Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16
Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. Nierenberg, Suppl 15, 13–17
Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Papakostas, Nov 1357–1361
Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. Brodaty, Jan 63–72
Relationship of personality disorders to treatment outcome in depressed outpatients. Mulder, Mar 259–264
Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. Cuffel, Apr 397–402
Residual symptoms in depression: can treatment be symptom-specific? Menza, May 516–523
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Sharpley, Feb 192–196
Role of algorithms in the detection and treatment of depression in primary care. Klinkman, Suppl 2, 19–23
Role of executive function in late-life depression. Alexopoulos, Suppl 14, 18–23
Role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. Fava M, Suppl 13, 26–29
Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. Simpson, Aug 959–965
Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662
Special issues related to the treatment of depression in women. Yonkers, Suppl 18, 8–13
Suicidal ideation and attempts among psychiatric patients with major depressive disorder. Sokero, Sept 1094–1100
Symptoms and circuits, pt 1: major depressive disorder [BRAINSTORMS]. Stahl, Nov 1282–1283
Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Fava M, Suppl 14, 30–34
Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369
Treating Depression and Anxiety to Remission: Use of Algorithms. Suppl 2, 1–36
Treating Depression: New Choices for a Chronic Problem. Suppl 18, 1–36
Treating depression to remission. Zajecka, Suppl 15, 7–12
Treatment of leuprolide-induced depression with intramuscular testosterone: a case report [letter]. Freeman, Mar 341–343
Treatment strategies for sleep disturbance in patients with depression. Doghramji, Suppl 14, 24–29

Dermatology

How common is obsessive-compulsive disorder in a dermatology outpatient clinic? Fineberg, Feb 152–155

Developmental Disorders

3-Year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Masi, Sept 1039–1047
Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. Tsiouris, Sept 1081–1090

Diabetes

Olanzapine/risperidone and diabetes risk [letter]. Lee; Gianfrancesco reply, July 847–848

Diet

Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214

Disability

Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182

Divalproex Sodium

Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. Chang KD, Aug 936–942
Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. Steiner, Oct 1183–1191
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
Divalproex versus olanzapine in mania [letter]. Vieta; Zajecka reply, Oct 1266–1267
Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846

Donepezil

Can donepezil be considered a mild antipsychotic in dementia treatment? a report of donepezil use in 6 patients [letter]. Terao, Nov 1392–1393
Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Stahl, Apr 466–472
Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521

Dosage
Chlorpromazine equivalent doses for the newer atypical antipsychotics. Woods, June 663–667
Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34
Droperidol
Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505
Drug Abuse
Psychometric evaluation of the Alcohol Use Disorders Identification Test and short Drug Abuse Screening Test with psychiatric patients in India. Carey KB, July 767–774
Drug Administration
Can long-term treatment with antidepressant drugs worsen the course of depression? Fava GM, Feb 123–133
Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Ereshefsky, Suppl 16, 18–23
Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19
Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. Brook, Suppl 19, 13–18
Potential new drug delivery systems for antidepressants: an overview. Kilts, Suppl 18, 31–33
Relapse and rehospitalization: comparing oral and depot antipsychotics. Schooler, Suppl 16, 14–17
Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane, Suppl 16, 34–40
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker, Oct 1250–1257
Duloxetine
Duloxetine in the long-term treatment of major depressive disorder. Raskin, Oct 1237–1244
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Schatzberg, Suppl 13, 30–37
Word of caution about the implied role for duloxetine in pain management [letter]. Lotsch, Oct 1276
Economics see Costs of Medical Care
Edema
Olanzapine-associated bilateral pedal edema [letter]. Christensen, Aug 972
Education
Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. Colom, Sept 1101–1105
Eicosapentaenoic Acid
Evidence that eicosapentaenoic acid is effective in treating autism [letter]. Johnson, July 848–849
Elderly
Aggression in the elderly. Brodaty, Suppl 4, 36–43
Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482
Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Lavretsky, Dec 1410–1414
Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport, Sept 1065–1074
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852
Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Oslin, Aug 875–882
Role of executive function in late-life depression. Alexopoulos, Suppl 14, 18–23
Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182
Treatment of agitation in bipolar disorder across the life cycle. Alderfer, Suppl 4, 3–9
Use of atypical antipsychotics in nursing homes. Liperoti, Sept 1106–1112
Electroconvulsive Therapy
Dilemma of unmodified electroconvulsive therapy [commentary]. Andrade, Oct 1147–1152
Electroconvulsive therapy update: recognizing and treating psychotic depression [editorial]. Fink, Mar 232–234
Long-term follow-up of magnetic resonance–detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy. Obergriesser, July 775–780
Pretreatment with ibuprofen to prevent electroconvulsive therapy–induced headache. Leung, May 551–553
E-mail
Suggested guidelines for e-mail communication in psychiatric practice. Silk, July 799–806
Epilepsy
Case report of hypomania following vagus nerve stimulation for refractory epilepsy [letter]. Klein, Apr 485–486
Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34
Erectile Dysfunction
Aging male: androgens, erectile dysfunction, and depression. Seidman, Suppl 10, 31–37
Antidepressant-related erectile dysfunction management via avoidance, switching, antidepressants, antidotes, and adaptation. Labbate, Suppl 10, 11–19
Depression: links with ischemic heart disease and erectile dysfunction. Rosen, Suppl 10, 25–30
Introduction: erectile dysfunction and comorbid depression: prevalence, treatment strategies, and associated medical conditions. Nurnberg, Suppl 10, 3–4
Prevalence of antidepressant-associated erectile dysfunction. Rosen, Suppl 10, 5–10
Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. Nurnberg, Suppl 10, 20–25
Escitalopram
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Stahl, Nov 1322–1327
Estrogen
Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479
Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118
Ethnicity
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. Opolka, June 635–639
Ethnicity and diagnosis in patients with affective disorders. Strakowski, July 747–754
Executive Dysfunction
Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17
Differential diagnosis of fatigue and executive dysfunction in primary care. Lieberman, Suppl 14, 40–43
Fatigue and executive dysfunction in the primary care setting [Primary Care commentary]. Culpepper, Suppl 14, 5
Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction. Stahl, Suppl 14, 3–4
Role of executive function in ADHD. Swanson, Suppl 14, 35–39
Role of executive function in late-life depression. Alexopoulos, Suppl 14, 18–23
Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Fava M, Suppl 14, 30–34
Exercise
Aerobic endurance exercise improves executive functions in depressed patients. Kubesch, Sept 1005–1012
Expert Consensus Guideline Series
Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100
Extrapyramidal Syndrome
Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906
Family Therapy
Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Miklowitz, Feb 182–191
Fatigue
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. DeBattista, Sept 1057–1064

Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17
Differential diagnosis of fatigue and executive dysfunction in primary care. Lieberman, Suppl 14, 40–43
Effectiveness of citalopram for idiopathic chronic fatigue. Hartz, Aug 927–935
Fatigue and executive dysfunction in the primary care setting [Primary Care commentary]. Culpepper, Suppl 14, 5
Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction. Stahl, Suppl 14, 3–4
Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Fava M, Suppl 14, 30–34
Fluoxetine
Citalopram treatment of fluoxetine-intolerant depressed patients. Calabrese, May 562–567
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229
Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926
Double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Barbosa, Apr 403–407
Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality [letter]. Chollet, Oct 1268–1269
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Corya, Nov 1349–1356
Fluvoxamine
Double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Hollander E, June 640–647
Formularies
Case for Physician Choice: Implications for Restricted Formularies. Suppl 17, 1–40
Impact of formularies on clinical innovation. Goodwin, Suppl 17, 11–14
Weighing the evidence: trends in managed care formulary decision making. de Lissovoy, Suppl 17, 29–32
Fosphenytoin
Intravenous fosphenytoin in acute mania. Applebaum, Apr 408–409
Gamma-Aminobutyric Acid
GABA systems, benzodiazepines, and substance dependence. Malcolm, Suppl 3, 36–40
Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. Chang, Suppl 3, 7–14
New molecular targets for antianxiety interventions. Gorman, Suppl 3, 28–35
Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems. Kalin, Suppl 3, 41–44
Role of GABA in anxiety disorders. Lydiard, Suppl 3, 21–27
Role of GABA in neuropsychiatric disorders: a review of GABA agents. Suppl 3, 1–47
Gender
Do antidepressants induce rapid cycling? a gender-specific association. Yildiz, July 814–818
Gender differences in pathological gambling. Ibáñez, Mar 295–301
Generalized Anxiety Disorder
Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Stocchi, Mar 250–258
Hydroxyzine for generalized anxiety disorder [letter]. Sagduyu, Mar 343
Randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. Bonne, Mar 282–287
Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Rosenthal, Oct 1245–1249
Treating generalized anxiety disorder. Gorman, Suppl 2, 24–29
Genetics
Deconstructing psychiatric disorders, pt 1: genotypes, symptom phenotypes, and endophenotypes [BRAINSTORMS]. Stahl, Sept 982–983
Gepirone
Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. Feiger, Mar 243–249
Geriatric Psychiatry see Elderly
Government
Government perspective [commentary]. Parks, Suppl 17, 37–38
Gynecomastia
Case of gynecomastia during paroxetine therapy [letter]. Damsa, Aug 971
Habit Reversal
Evaluating the efficacy of habit reversal: comparison with a placebo control. Twohig, Jan 40–48
Hair Pulling see Trichotillomania
Hallucinations
Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521
Haloperidol
Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760
Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. Oosthuizen, Sept 1075–1080
Headache
Pretreatment with ibuprofen to prevent electroconvulsive therapy–induced headache. Leung, May 551–553
Heart Disease
Depression: links with ischemic heart disease and erectile dysfunction. Roose, Suppl 10, 26–30
Hepatitis
Critical review of selective serotonin reuptake inhibitor–associated bleeding: balancing the risk of treating hepatitis C–infected patients. Weinrieb, Dec 1502–1510
Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C–seropositive state hospital patients: results from Oregon State Hospital. Meyer, May 540–545
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Kraus, June 708–714
Herbal Preparations
Acute liver failure after administration of the herbal tranquilizer kava-kava (*Piper methysticum*) [letter]. Brauer, Feb 216–218
HIV
Open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. Carvalhal, Apr 421–424
Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C–seropositive state hospital patients: results from Oregon State Hospital. Meyer, May 540–545
Homeopathy
Randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. Bonne, Mar 282–287
Hormones
Aging male: androgens, erectile dysfunction, and depression. Seidman, Suppl 10, 31–37
Human Immunodeficiency Virus see HIV
Hydroxyzine
Hydroxyzine for generalized anxiety disorder [letter]. Sagduyu, Mar 343
Hyperglycemia
Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. Sernyak, May 605–608
Hypnotics
Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Stahl, Apr 466–472
Hypomania
Case report of hypomania following vagus nerve stimulation for refractory epilepsy [letter]. Klein, Apr 485–486
Ibuprofen
Pretreatment with ibuprofen to prevent electroconvulsive therapy–induced headache. Leung, May 551–553
Imipramine
Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662
Impulsivity
Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85
Incontinence
Case report of olanzapine-induced fecal incontinence [letter]. Mendhekar, Mar 339

India
Psychometric evaluation of the Alcohol Use Disorders Identification Test and short Drug Abuse Screening Test with psychiatric patients in India. Carey KB, July 767–774
Infants
Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80
Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412
Insomnia
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229
Insulin
Olanzapine induces insulin resistance: results from a prospective study. Ebenbichler, Dec 1436–1439
Intelligence
Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93
Interferon
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Kraus, June 708–714
Internet
Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215
Italy
Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Percudani, Nov 1293–1299
Journal of Clinical Psychiatry
On-line manuscript submission and peer review. Jan 6–7
Happy New Year! [editorial] Gelenberg, Jan 8–11
Kava-Kava
Acute liver failure after administration of the herbal tranquilizer Kava-Kava (*Piper methysticum*) [letter]. Brauer, Feb 216–218
Lamotrigine
Double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Barbosa, Apr 403–407
Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201
Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Calabrese, Sept 1013–1024
Leuprolide
Treatment of leuprolide-induced depression with intramuscular testosterone: a case report [letter]. Freeman, Mar 341–343
Levetiracetam
Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. Grunze, July 781–784
LHRH Agonists
Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone–releasing hormone: a systematic review. Briken, Aug 890–897
Life Chart Method
Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. Post, June 680–690
Light Therapy see Phototherapy
Linezolid
Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants [letter]. Aga, May 609–610
Lipids
Effects of mirtazapine on plasma lipid profiles in healthy subjects. Nicholas, Aug 883–889
Lithium
Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43
Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Kennedy, Apr 439–444
Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37
Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334
Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52
Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Calabrese, Sept 1013–1024
Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Hartong, Feb 144–151
Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24
Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846
Use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Gray, Suppl 5, 3–17
Liver Failure
Acute liver failure after administration of the herbal tranquilizer kava-kava (*Piper methysticum*). Brauer, Feb 216–218
Magnesium
Oral magnesium ion shortens prolonged QTc interval. Bachman, June 733–734. Correction, Aug 972
Magnetic Resonance Imaging see Brain Imaging
Managed Care
Health care organization perspective [commentary]. Goldman, Suppl 17, 35–36
Weighing the evidence: trends in managed care formulary decision making. de Lissovoy, Suppl 17, 29–32
Mania
Divalproex versus olanzapine in mania [letter]. Vieta; Zajecka reply, Oct 1266–1267
Drug combinations for mania. Mondimore, Suppl 5, 25–31
Intravenous fosphenytoin in acute mania. Applebaum, Apr 408–409
Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. Grunze, July 781–784
Mania associated with initiation of ziprasidone [letter]. Nolan, Mar 336
Mania from dose-related ziprasidone augmentation of an SSRI [letter]. Privitera, Nov 1393–1394
1-Year follow-up of patients treated with risperidone and topiramate for a manic episode. Vieta, July 834–839
Maudsley Bipolar Disorder Project
Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93
Medicaid
Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill. Soumerai, Suppl 17, 19–22
Melancholia
Enlargement of brain cerebrospinal fluid spaces as a predictor of poor clinical outcome in melancholia. Cardoner, June 691–697
Memory
Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93
Men
Hostility during admission interview as a short-term predictor of aggression in acute psychiatric male inpatients. Troisi, Dec 1460–1464
Increased cholesterol levels during paroxetine administration in healthy men. Lara, Dec 1455–1459
Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? Kanayama, Feb 156–160
Mental Retardation
Possible antidepressant-associated activation of mania and psychosis in the mentally retarded: four case reports [letter]. Sahay, Apr 481–482
Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62
Metabolic Syndrome
Metabolic syndrome in patients with schizophrenia. Heiskanen, May 575–579
Metabolism
Olanzapine elevation of serum creatine kinase [letter]. Martí-Bonmatí, Apr 483–484
Olanzapine induces insulin resistance: results from a prospective study. Ebenbichler, Dec 1436–1439
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Atmaca, May 598–604
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134
Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62

Methylphenidate
Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Lavretsky, Dec 1410–1414
Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18
Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169
Mirtazapine
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229
Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Szegedi, Apr 413–420
Effects of mirtazapine on plasma lipid profiles in healthy subjects. Nicholas, Aug 883–889
Modafinil
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. DeBattista, Sept 1057–1064
Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485–486
Mood
Effects of breathing-related sleep disorders on mood disturbances in the general population. Ohayon, Oct 1195–1200
Gender-specific considerations in the treatment of mood disorders in women across the life cycle. Cohen, Suppl 15, 18–29
Impact of attempted suicide on the symptoms and course of mood disorders. Sakamoto, Oct 1210–1216
Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic. Dilsaver, Oct 1170–1176
"Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701
Mood Stabilizers
Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335
Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43
Introduction: using the newer pharmacotherapeutic agents as mood stabilizers in bipolar spectrum disorders. Chengappa, Suppl 8, 3–4
New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24
Use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Gray, Suppl 5, 3–17
Myocardial Infarction
Trajectories of posttraumatic stress disorder following myocardial infarction: a prospective study. Ginzburg, Oct 1217–1223
Nail Biting
Evaluating the efficacy of habit reversal: comparison with a placebo control. Twohig, Jan 40–48
National Depressive and Manic-Depressive Association
Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. Hirschfeld, Feb 161–174
Nausea
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19
Nefazodone
Effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. Neylan, Apr 445–450
Negative Symptoms
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor-α and to interferon-γ: a case report [letter]. Skurkovich SV, June 734–735
Negative symptoms in depressed and schizophrenic patients: how do they differ? Bottlender, Aug 954–958
Neuroimaging see Brain Imaging
Neuroreceptors
Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Richelson, Suppl 13, 5–12
Neuroreceptor mechanisms of aggression and its treatment. Swann, Suppl 4, 26–35
Role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. Fava M, Suppl 13, 26–29
Nonsteroidal Anti-Inflammatory Drugs
Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334
Nortriptyline
Nortriptyline for treatment-resistant depression. Nierenberg, Jan 35–39
Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Papakostas, Nov 1357–1361
Nursing Homes
Use of atypical antipsychotics in nursing homes. Liperoti, Sept 1106–1112
Nutrition
Nutritional approach to bipolar disorder [letter]. Simmons; Simpson reply, Mar 338–339
Obsessive-Compulsive Disorder
Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Hollander E, Sept 1113–1121
Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. Poyurovsky, Nov 1300–1307
Double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Hollander E, June 640–647
How common is obsessive-compulsive disorder in a dermatology outpatient clinic? Fineberg, Feb 152–155
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611
Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. Hewlett, Sept 1025–1030
Venlafaxine in treatment-resistant obsessive-compulsive disorder. Hollander E, May 546–550. Correction, Aug 972
Olanzapine
Case report of olanzapine-induced fecal incontinence [letter]. Mendhekar, Mar 339
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
Divalproex versus olanzapine in mania [letter]. Vieta; Zajecka reply, Oct 1266–1267
Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852
High-dose olanzapine and prolactin levels. Karagianis, Oct 1192–1194
Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Corya, Nov 1349–1356
Olanzapine-associated bilateral pedal edema [letter]. Christensen, Aug 972
Olanzapine elevation of serum creatine kinase [letter]. Martí-Bonmatí, Apr 483–484
Olanzapine for cocaine cravings and relapse prevention [letter]. Sattar, Aug 969
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Janowsky, Oct 1258–1265

Olanzapine induces insulin resistance: results from a prospective study. Ebenbichler, Dec 1436–1439
Olanzapine/risperidone and diabetes risk [letter]. Lee; Gianfrancesco reply, July 847–848
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611
Open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. Stewart, Jan 49–52
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor, May 589–597
Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Godleski, Feb 119–122

Olfaction
Olfaction as a traumatic reminder in posttraumatic stress disorder: case reports and review. Vermetten, Feb 202–207

Ondansetron
Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. Hewlett, Sept 1025–1030

Oregon
Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C–seropositive state hospital patients: results from Oregon State Hospital. Meyer, May 540–545

Outcome
Recent Developments in Achieving Depression Remission. Suppl 13, 1–40

Outpatients
Suicide risk of discharged psychiatric patients. Ho, June 702–707

Overdose
Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215

Oxcarbazepine
Oxcarbazepine treatment of bipolar disorder. Ghaemi, Aug 943–945

Pain
Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23
Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes [BRAINSTORMS]. Stahl, Aug 863–864
Word of caution about the implied role for duloxetine in pain management [letter]. Leo, Oct 1270

Panic Disorder
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Stahl, Nov 1322–1327
Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662
Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389

Paraphilias
Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone–releasing hormone: a systematic review. Briken, Aug 890–897

Paresthesia
Serotonin reuptake inhibitors and shocklike paresthesia [letter]. de Graaf, Aug 969–971

Paroxetine
Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Hollander E, Sept 1113–1121
Case of gynecomastia during paroxetine therapy [letter]. Damsa, Aug 971
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Szegedi, Apr 413–420
Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Stocchi, Mar 250–258
Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport, Sept 1065–1074
Increased cholesterol levels during paroxetine administration in healthy men. Lara, Dec 1455–1459
Paroxetine-induced somnambulism [letter]. Kawashima, Apr 483
Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Rosenthal, Oct 1245–1249

Pathological Crying
Venlafaxine for pathological crying after stroke [letter]. Smith AG, June 731–732

Pathological Gambling
Factors at play in faster progression for female pathological gamblers: an exploratory analysis. Tavares, Apr 433–438
Gender differences in pathological gambling. Ibáñez, Mar 295–301
Suicide attempts among veterans seeking treatment for pathological gambling. Kausch, Sept 1031–1038

Patient Advocacy
Advocacy perspective [commentary]. Fitzpatrick, Suppl 17, 39–40

Personality Disorders
Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
Relationship of personality disorders to treatment outcome in depressed outpatients. Mulder, Mar 259–264

Pharmacoeconomics
Case for Physician Choice: Implications for Restricted Formularies. Suppl 17, 1–40
Purchasing community perspective [commentary]. Moore MC, Suppl 17, 33–34

Pharmacokinetics
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19
Psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Stahl, Suppl 19, 6–12

Phentermine
Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215

Phototherapy
Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. Benedetti, June 648–653

Physical Symptoms
Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes [BRAINSTORMS]. Stahl, July 745–746
Depression with physical symptoms: treating to remission. Fava M, Suppl 7, 24–28
Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23
Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes [BRAINSTORMS]. Stahl, Aug 863–864
Physical symptoms of depression as a public health concern. Sartorius, Suppl 7, 3–4
Physical symptoms of depression: unmet needs. Greden, Suppl 7, 5–11
Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16

Physician-Patient Relations
Suggested guidelines for e-mail communication in psychiatric practice. Silk, July 799–806

Piroxicam
Carbamazepine treatment of adverse psychiatric effects after treatment with the nonsteroidal anti-inflammatory drug piroxicam [letter]. Eser, July 852–854

Placebo Control
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. Hummer, Mar 277–281

Polydipsia
Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report [letter]. Montgomery, Mar 339–341

Postpartum Psychosis
Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118
Relationship between postpartum psychosis and bipolar disorder: a review. Chaudron, Nov 1284–1292

Posttraumatic Stress Disorder
AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD [letter]. Zullino, Feb 219–220
Effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. Neylan, Apr 445–450
Mental health treatment received by primary care patients with posttraumatic stress disorder. Rodriguez, Oct 1230–1236
Olfaction as a traumatic reminder in posttraumatic stress disorder: case reports and review. Vermetten, Feb 202–207
Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181
Tiagabine for posttraumatic stress disorder: a case series of 7 women. Taylor FB, Dec 1421–1425

Trajectories of posttraumatic stress disorder following myocardial infarction: a prospective study. Ginzburg, Oct 1217–1223
Predictors
Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389
Pregnancy
Clozapine and pregnancy [letter]. Mendhekar, July 850
Premenstrual Dysphoric Disorder
Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Endicott, Dec 1511–1516
Prescriptions
Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215
Priapism
Case of risperidone-induced priapism [letter]. Relan, Apr 482–483
Priapism associated with risperidone: a case report [letter]. Bourgeois, Feb 218–219
Prolonged erections associated with ziprasidone treatment: a case report [letter]. Reeves, Jan 97–98
Successful treatment with clozapine at higher doses after clozapine-induced priapism [letter]. de Nesnera, Nov 1394–1395
Primary Care
Attending to anxiety disorders in primary care. Stein, Suppl 15, 35–39
Differential diagnosis of fatigue and executive dysfunction in primary care. Lieberman, Suppl 14, 40–43
Difficult-to-treat depressions: a primary care perspective. Manning, Suppl 1, 24–31
Fatigue and executive dysfunction in the primary care setting [PC commentary]. Culpepper, Suppl 14, 5
Mental health treatment received by primary care patients with posttraumatic stress disorder. Rodriguez, Oct 1230–1236
Role of algorithms in the detection and treatment of depression in primary care. Klinkman, Suppl 2, 19–23
Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389
Use of algorithms to treat anxiety in primary care. Culpepper, Suppl 2, 30–33
Prolactin
High-dose olanzapine and prolactin levels. Karagianis, Oct 1192–1194
Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369
Psychiatric Emergency Service
Treating aggression in the psychiatric emergency service. Hughes, Suppl 4, 10–15
Psychometric Tests
Psychometric evaluation of the alcohol use disorders identification test and short drug abuse screening test with psychiatric patients in India. Carey KB, July 767–774
Psychopharmacology
Deconstructing psychiatric disorders, pt 2: an emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist [BRAINSTORMS]. Stahl, Oct 1145–1146
Psychosis see also specific disorders
Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report [letter]. Montgomery, Mar 339–341
Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100
Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. Brodaty, Jan 63–72
Psychotherapy
Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Miklowitz, Feb 182–191
QTc
Oral magnesium ion shortens prolonged QTc interval. Bachman, June 733–734
Oral magnesium ion shortens prolonged QTc interval [letter]. Bachman, June 733–734. Correction, Aug 972
Quetiapine and QTc issues: a case report [letter]. Gupta S, May 612–613
Quality of Life
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
Quetiapine
Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report [letter]. Montgomery JH, Mar 339–341
Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Velligan, May 524–531
Prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Sasaki, Nov 1316–1321
Quetiapine and QTc issues: a case report [letter]. Gupta S, May 612–613
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134
Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521
Rabbit Syndrome
Clozapine-induced rabbit syndrome [letter]. Sethi, Feb 219
Race
Racial differences in use of antipsychotics among patients with bipolar disorder [letter]. Szarek; Fleck reply, May 614–615
Rapid Cycling
Do antidepressants induce rapid cycling? a gender-specific association. Yildiz, July 814–818
Reboxetine
Case of risperidone-induced priapism [letter]. Relan, Apr 482–483
Open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. Carvalhal, Apr 421–424
Receptors
Clozapine-induced rabbit syndrome [letter]. Sethi, Feb 219
Remission
Effectiveness of antidepressants: comparative remission rates. Thase, Suppl 2, 3–7
Treating Depression and Anxiety to Remission. Suppl 15, 1–48
Using treatment algorithms to bring patients to remission. Trivedi, Suppl 2, 8–13
Risperidone
Case of risperidone-induced priapism [letter]. Relan, Apr 482–483
Charles Bonnet Syndrome with visual hallucinations of childhood experience: successful treatment of 1 patient with risperidone [letter]. Maeda, Sept 1131–1132
Clinical guidelines: dosing and switching strategies for long-acting risperidone. Marder, Suppl 16, 41–46
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Lane, Mar 316–320
Olanzapine/risperidone and diabetes risk [letter]. Lee; Gianfrancesco reply, July 847–848
1-Year follow-up of patients treated with risperidone and topiramate for a manic episode. Vieta, July 834–839
Priapism associated with risperidone: a case report [letter]. Bourgeois, Feb 218–219
Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369
Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Sharpley, Feb 192–196
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker D, July 761–766
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor DM, May 589–597
Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai, Nov 1342–1348
Risperidone in the treatment of schizotypal personality disorder. Koenigsberg, June 628–634
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134

3-Year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Masi, Sept 1039–1047
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker, Oct 1250–1257
Rofecoxib
Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334
Schizoaffective Disorder
Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118
Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
Schizophrenia
Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Pigott, Sept 1048–1056
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. Hummer, Mar 277–281
Attribution of somatization in schizophrenia patients: a naturalistic follow-up study. Ritsner, Nov 1370–1378
Bipolar disorder and schizophrenia: distinct illnesses or a continuum? Möller, Suppl 6, 23–27
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
Combination therapy: is clinical practice leading the way? [letter] Welch; Stahl reply, Jan 94–96
Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. Poyurovsky, Nov 1300–1307
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Weiden, May 580–588
Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760
Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Lane, Mar 316–320
Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. Jaffe, Suppl 17, 3–6
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. Opolka, June 635–639
Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor-α and to interferon-γ: a case report [letter]. Skurkovich SV, June 734–735
Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906
Metabolic syndrome in patients with schizophrenia. Heiskanen, May 575–579
Negative symptoms in depressed and schizophrenic patients: how do they differ? Bottlender, Aug 954–958
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611
Partial compliance and patient consequences in schizophrenia: our patients can do better. Keith, Nov 1308–1315
Partial Compliance: The Need for Long-Acting Atypical Antipsychotics. Suppl 16, 1–49
Polypharmacy in patients with schizophrenia. McCue, Sept 984–989
Polypharmacy in schizophrenia: a fuzzy concept [letter]. Freudenreich; Stahl reply, Sept 1132–1133
Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
Reducing the Risk for Suicide in Schizophrenia and Affective Disorders [Academic Highlights]. Sept 1122–1129
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker, July 761–766
Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. Harkavy-Friedman, Aug 871–874
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Godleski, Feb 119–122
Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker, Oct 1250–1257
Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. Sernyak, May 605–608
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient [letter]. Hofer, Oct 1267–1268
Ziprasidone in Schizophrenia: From Acute Treatment to Long-Term Management. Suppl 19, 1–49
Schizotypal Personality Disorder
Risperidone in the treatment of schizotypal personality disorder. Koenigsberg, June 628–634
Sedation
Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505
Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485–486
Selective Serotonin Reuptake Inhibitors
Burning mouth syndrome as a side effect of SSRIs [letter]. Levenson; Maina reply, Mar 336–338
Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Endicott, Dec 1511–1516
Critical review of selective serotonin reuptake inhibitor–associated bleeding: balancing the risk of treating hepatitis C–infected patients. Weinrieb, Dec 1502–1510
Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330
High-dose sildenafil citrate for selective serotonin reuptake inhibitor–associated ejaculatory delay: open clinical trial. Seidman, June 721–725
Long-term side effects of SSRIs: sexual dysfunction and weight gain. Hirschfeld, Suppl 18, 20–24
Serotonin reuptake inhibitors and shocklike paresthesia [letter]. de Graaf, Aug 969–971
Selegiline
Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214
Self-Injurious Behavior
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Janowsky, Oct 1258–1265
Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. Tsiouris, Sept 1081–1090
Sertraline
Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. Liebowitz, July 785–792
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611
Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Oslin, Aug 875–882
Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. Simpson, Aug 959–965

Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662

Sexual Function

Erectile Dysfunction and Comorbid Depression: Prevalence, Treatment Strategies, and Associated Medical Conditions. Suppl 10, 1–37

Evaluation of sexual changes after stroke. Giaquinto, Mar 302–307

High-dose sildenafil citrate for selective serotonin reuptake inhibitor–associated ejaculatory delay: open clinical trial. Seidman, June 721–725

Long-term side effects of SSRIs: sexual dysfunction and weight gain. Hirschfeld, Suppl 18, 20–24

Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182

Sildenafil Citrate

High-dose sildenafil citrate for selective serotonin reuptake inhibitor–associated ejaculatory delay: open clinical trial. Seidman, June 721–725

Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. Nurnberg, Suppl 10, 20–25

Sleep

Effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. Neylan, Apr 445–450

Effects of breathing-related sleep disorders on mood disturbances in the general population. Ohayon, Oct 1195–1200

Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Sharpley, Feb 192–196

Treatment strategies for sleep disturbance in patients with depression. Doghramji, Suppl 14, 24–29

Social Anxiety Disorder

Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. Liebowitz, July 785–792

Somatic Symptoms see Physical Symptoms

Somatization

Attribution of somatization in schizophrenia patients: a naturalistic follow-up study. Ritsner, Nov 1370–1378

Somnambulism

Paroxetine-induced somnambulism [letter]. Kawashima, Apr 483

Stanley Foundation Bipolar Network

Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. Leverich, May 506–515

Steatohepatitis

Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics [letter]. Haberfellner, July 851

Steroids

Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? Kanayama, Feb 156–160

St. John's Wort

Safety of St. John's Wort (*Hypericum perforatum*) during breastfeeding. Lee A, Aug 966–968

Stimulants

Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23

Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18

Does stimulant treatment lead to substance use disorders? Faraone, Suppl 11, 9–13

Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8

Stroke

Evaluation of sexual changes after stroke. Giaquinto, Mar 302–307

Venlafaxine for pathological crying after stroke [letter]. Smith AG, June 731–732

Substance Abuse

Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23

Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18

Does stimulant treatment lead to substance use disorders? Faraone, Suppl 11, 9–13

GABA systems, benzodiazepines, and substance dependence. Malcolm, Suppl 3, 36–40

Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201

Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? Kanayama, Feb 156–160

Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8

Suicide

Agitation and inpatient suicide [letter]. Sharma V; Busch reply, Dec 1517–1518

Clinical correlates of inpatient suicide. Busch, Jan 14–19

Effectiveness of close watch precautions in suicidal patients [letter]. Aldrich; Fawcett reply, Dec 1520

Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760

Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. Leverich, May 506–515

Impact of attempted suicide on the symptoms and course of mood disorders. Sakamoto, Oct 1210–1216

Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52

Preventing inpatient suicide [commentary]. Goodwin, Jan 12–13

Reducing the risk for suicide in schizophrenia and affective disorders [Academic Highlights]. Sept 1122–1129

Suicidal ideation and attempts among psychiatric patients with major depressive disorder. Sokero, Sept 1094–1100

Suicide attempts among veterans seeking treatment for pathological gambling. Kausch, Sept 1031–1038

Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. Harkavy-Friedman, Aug 871–874

Suicide risk of discharged psychiatric patients. Ho, June 702–707

Treatment of anxiety in suicidal patients [letter]. Rich; Fawcett reply, Dec 1518–1519

Tardive Dyskinesia

Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. Oosthuizen, Sept 1075–1080

Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai, Nov 1342–1348

Testosterone

Treatment of leuprolide-induced depression with intramuscular testosterone: a case report [letter]. Freeman, Mar 341–343

Tetrahydrocannabinol

Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette Syndrome: a 6-week randomized trial. Müller-Vahl, Apr 459–465

Texas

Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. Opolka, June 635–639

Texas Medication Algorithm Project

Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Suppes, Apr 370–382

Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369

Thromboembolism

Clozapine and venous thromboembolism: further evidence [letter]. Selten, May 609

Tiagabine

Tiagabine for posttraumatic stress disorder: a case series of 7 women. Taylor FB, Dec 1421–1425

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Rosenthal, Oct 1245–1249

Tics

Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette Syndrome: a 6-week randomized trial. Müller-Vahl, Apr 459–465

Topiramate

AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD [letter]. Zullino, Feb 219–220

1-year follow-up of patients treated with risperidone and topiramate for a manic episode. Vieta, July 834–839

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 1: improvement in binge and purge measures. Hoopes, Nov 1335–1341

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 2: improvement in psychiatric measures. Hedges, Dec 1449–1454

Two cases of alcohol craving curbed by topiramate [letter]. Komanduri, May 612
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient [letter]. Hofer, Oct 1267–1268
Tourette Syndrome
Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette Syndrome: a 6-week randomized trial. Müller-Vahl, Apr 459–465
Transcranial Magnetic Stimulation
Efficacy and safety of bilateral rTMS in medication-resistant depression [letter]. Cohen, May 613–614
High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. Eichhammer, Aug 951–953
Treatment Outcome
Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335
Can long-term treatment with antidepressant drugs worsen the course of depression? Fava GA, Feb 123–133
Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330
Relationship of personality disorders to treatment outcome in depressed outpatients. Mulder, Mar 259–264
Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. Cuffel, Apr 397–402
Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389
Trichotillomania
Open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. Stewart, Jan 49–52
United States
Economic burden of depression in the United States: how did it change between 1990 and 2000? Greenberg, Dec 1465–1475
Vagus Nerve Stimulation
Case report of hypomania following vagus nerve stimulation for refractory epilepsy [letter]. Klein, Apr 485–486
Valproate
Use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Gray, Suppl 5, 3–17
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient [letter]. Hofer, Oct 1267–1268
Velocardiofacial Syndrome
Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169
Venlafaxine
Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Oslin, Aug 875–882
Venlafaxine for pathological crying after stroke [letter]. Smith AG, June 731–732
Venlafaxine in treatment-resistant obsessive-compulsive disorder. Hollander E, May 546–550. Correction, Aug 972
Veterans
Suicide attempts among veterans seeking treatment for pathological gambling. Kausch, Sept 1031–1038
Use of antidepressants in alcohol-dependent veterans. Petrakis, Aug 865–870
Violence
Mental disorder and serious violence: the victims. Johnston. July 819–824
Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505
Weight
Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. Keck, Dec 1426–1435
Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Lane, Mar 316–320
Long-term side effects of SSRIs: sexual dysfunction and weight gain. Hirschfeld, Suppl 18, 20–24
Reversal of antipsychotic-associated weight gain. O'Keefe, Aug 907–912
Safety of available agents used to treat bipolar disorder: focus on weight gain. Nemeroff, May 532–539
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134
Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412
Weight gain in the treatment of mood disorders. Aronne, Suppl 8, 22–29
Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62
Women
Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479
Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118
Factors at play in faster progression for female pathological gamblers: an exploratory analysis. Tavares, Apr 433–438
Gender-specific considerations in the treatment of mood disorders in women across the life cycle. Cohen, Suppl 15, 18–29
Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80
Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker D, July 761–766
Safety of St. John's Wort (*Hypericum perforatum*) during breastfeeding. Lee A, Aug 966–968
Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182
Special issues related to the treatment of depression in women. Yonkers, Suppl 18, 8–13
Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412
Ziprasidone
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Weiden, May 580–588
Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. Brook, Suppl 19, 13–18
Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management. Kane, Suppl 19, 3–5
Maintaining symptom control: review of ziprasidone long-term efficacy data. Schooler, Suppl 19, 26–32
Mania associated with initiation of ziprasidone [letter]. Nolan, Mar 336
Mania from dose-related ziprasidone augmentation of an SSRI [letter]. Privitera, Nov 1393–1394
Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. Kane, Suppl 19, 19–25
Prolonged erections associated with ziprasidone treatment: a case report [letter]. Reeves, Jan 97–98
Psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Stahl, Suppl 19, 6–12
Tolerability of ziprasidone: an expanding perspective. Daniel, Suppl 19, 40–49
Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62
Ziprasidone and cognition: the evolving story. Harvey, Suppl 19, 33–39
Ziprasidone augmentation of clozapine in 11 patients [letter]. Kaye, Feb 215–216

The Journal of Clinical Psychiatry

Author Index to Volume 64: January 2003 Through December 2003

Aboujaoude E, Gamel N, Koran LM. 1-Year naturalistic follow-up of patients with compulsive shopping disorder. Aug 946–950
Adebimpe VR see Strakowski SM
Adleman N see Chang KD
Aga VM, Barklage NE, Jefferson JW. Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants [letter]. May 609–610
Air TM see Chan AOM
Akande B see Cohen CI
Akiskal HS see Dilsaver SC
Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. Suppl 4, 3–9
Aldrich CK. Effectiveness of close watch precautions in suicidal patients [letter with reply]. Dec 1520
Aleksandrovsky YA see Skurkovich SV
Alexander AB see Soares CN
Alexopoulos GS. Role of executive function in late-life depression. Suppl 14, 18–23
Allen A see Hollander E
Allen MH see Alderfer BS
Alonso J, Bernet W. Review of Gutheil TG, Simon RI: *Mastering Forensic Psychiatric Practice: Advanced Strategies for the Expert Witness.* Aug 973
Alpert JE see Nierenberg AA; Papakostas GI
Altshuler KZ see Rush AJ; Suppes T
Altshuler LL see Hendrick V; Leverich GS; Post RM
Amassian VE see Cohen CI
Ames D see Brodaty H
Amicone J see Strakowski SM
Amsterdam JD. Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Feb 208–214
Andersen SW see Corya SA
Andrade C, Shah N, Tharyan P. Dilemma of unmodified electroconvulsive therapy [commentary]. Oct 1147–1152
Andreatini R see Chollet CAS
Anghelescu I see Szegedi A
Applebaum J, Levine J, Belmaker RH. Intravenous fosphenytoin in acute mania. Apr 408–409
Appleton WS. Review of Stein DJ, Hollander E (eds): *American Psychiatric Publishing Textbook of Anxiety Disorders.* May 617–618
Apter A see Gothelf D
Arató M see Lepola U
Archer SL see Lara N
Aripiprazole Study Group see Pigott TA
Arnold LM see Strakowski SM
Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. Suppl 8, 22–29
Ascher J see Calabrese JR
Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. May 598–604
Auriacombe M see Weinrieb RM
Austin C see Lepola U
Azocar F see Cuffel BJ
Baca-Garcia E see Oquendo MA
Bacher R see Weiss U
Bachman DM. Oral magnesium ion shortens prolonged QTc interval [letter]. June 733–734. Correction, Aug 972
Bagby RM see Kennedy SH
Bai Y-M, Yu S-C, Lin C-C. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Nov 1342–1348
Baker GB see Lara N
Baker JD see Hirschfeld RMA
Bakker A see Vergouwen ACM
Baksh A see Karagianis JL
Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. Suppl 5, 44–52
Ballard CG. Reply to Snowdon J: Reporting changes in scores on the Cohen-Mansfield Agitation Inventory Subscales [letter]. June 732
Bandettini di Poggio A see Ciapparelli A
Banks A see Fineberg NA
Barbato LM see Hollander E
Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Apr 403–407
Barbui C see Percudani M
Barklage NE see Aga VM
Barkley RA see Fischer M
Barner JC see Opolka JL
Barnhill LJ see Janowsky DS
Beasley CM see Carlson CD
Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. July 761–766
Becker K see Brauer RB
Behnke K see Calabrese JR
Bellivier F see Henry C
Belmaker RH see Applebaum J
Belmonte de Abreu P see Carvalhal AS
Benazzi F. Anger in bipolar depression [letter with reply]. Apr 480–481
Benazzi F. Underdiagnosis of bipolar II disorders in the community [letter]. Sept 1130–1131
Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. June 648–653
Benjamin S. Review of Gualtieri CT: *Brain Injury and Mental Retardation: Psychopharmacology and Neuropsychiatry.* Dec 1522–1523
Benkert O see Szegedi A
Benlloch L see Cardoner N
Bennett MJ. Review of Dickey B, Sederer LI (eds): *Improving Mental Health Care: Commitment to Quality.* Apr 488–489
Bentler SE see Hartz AJ
Berg PH see Carlson CD
Berglund PA see Greenberg PE
Berk M see Barbosa L
Bernabei R see Liperoti R
Bernasconi A see Benedetti F
Berner W see Briken P
Bernet W. Review of Meyers WC: *Juvenile Sexual Homicide.* Apr 487
Bernet W see Alonso J
Berv DA see Ghaemi SN
Besson J see Zullino DF
Bhagwagar Z see Sharpley AL
Bhargava SC see Sethi S
Bhatia SC see Sattar SP
Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Suppl 11, 3–8
Biggs MM see Rush AJ; Suppes T
Binder C see Findling RL
Binder H see Eichhammer P
Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA. Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. Oct 1201–1209
Birnbaum HG see Greenberg PE
Birnbaum M see Hollander E
Blanco C see Ibáñez A
Blasey C see Chang KD
Bleich A see Ginzburg K
Bobadilla L see Brown ES
Bogetto F see Maina G

Bonne O, Shemer Y, Gorali Y, Katz M, Shalev AY. Randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. Mar 282–287
Born C see Grunze H
Bottai M see Ciapparelli A
Bottlender R, Sato T, Groll C, Jäger M, Kunze I, Möller H-J. Negative symptoms in depressed and schizophrenic patients: how do they differ? Aug 954–958
Bourgeois JA, Mundh H. Priapism associated with risperidone: a case report [letter]. Feb 218–219
Bowden CL see Calabrese JR
Bowers MB Jr see Klein JP; Sahay N
Brake KA see Hartz AJ
Brand-Gothelf A see Gothelf D
Brauer RB, Stangl M, Siewert JR, Pfab R, Becker K. Acute liver failure after administration of the herbal tranquilizer kava-kava (*Piper methysticum*) [letter]. Feb 216–218
Braus DF see Obergriesser T
Breier A see Feldman PD
Bremner JD see Vermetten E
Bretschneider V see Kubesch S
Briken P, Hill A, Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone–releasing hormone: a systematic review. Aug 890–897
Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Feb 134–143
Brodaty H, Draper BM, Millar J, Low L-F, Lie D, Sharah S, Paton H. Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. Jan 63–72
Brodaty H, Low L-F. Aggression in the elderly. Suppl 4, 36–43
Broekman TG see Hartong EGTM
Brook S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. Suppl 19, 13–18
Brovedani P see Masi G
Brown CM see Opolka JL
Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. Feb 197–201
Brown ES see Suppes T
Brown GR see Leung M
Brown LL, Tomarken AJ. Review of Griez EJL, Faravelli C, Nutt D, Zohar J (eds): *Anxiety Disorders: An Introduction to Clinical Management and Research*. Jan 100
Brown N see Kumar C
Bryson H see Stocchi F
Büller H see Selten J-P
Bullock KD see Koran LM
Burg M see Gothelf D
Burnham DR see Hollander E
Busch AB see Cuffel BJ
Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. Jan 14–19
Busch KA, Fawcett J, Jacobs DG. Reply to Sharma V: Agitation and inpatient suicide [letter]. Dec 1517–1518
Busch KA see Fawcett J
Buzzelli S see Giaquinto S
Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen O-P, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J, for the Lamictal 605 Study Group. Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Sept 1013–1024
Calabrese JR, Hirschfeld RMA, Reed M, Davies MA, Frye MA, Keck PE Jr, Lewis L, McElroy SL, McNulty JP, Wagner KD. Impact of bipolar disorder on a U.S. community sample. Apr 425–432
Calabrese JR, Londborg PD, Shelton MD, Thase ME. Citalopram treatment of fluoxetine-intolerant depressed patients. May 562–567
Calabrese JR see Hirschfeld RMA
Campbell CE see Oquendo MA
Campbell IC see Kumar C
Capece JA see Hedges DW; Hoopes SP
Cardoner N, Pujol J, Vallejo J, Urretavizcaya M, Deus J, López-Sala A, Benlloch L, Menchón JM. Enlargement of brain cerebrospinal fluid spaces as a predictor of poor clinical outcome in melancholia. June 691–697
Carey KB, Carey MP, Chandra PS. Psychometric evaluation of the Alcohol Use Disorders Identification Test and short Drug Abuse Screening Test with psychiatric patients in India. July 767–774
Carey MP see Carey KB
Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Aug 898–906
Carmassi C see Ciapparelli A
Carmody TJ see Rush AJ; Suppes T
Carpenter D see Kane JM
Carson WH see Pigott TA
Caruso KA. Review of Spinelli MG (ed): *Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill*. Sept 1135–1136
Carvalhal AS, Belmonte de Abreu P, Spode A, Correa J, Kapczinski F. Open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. Apr 421–424
Cassano GB see Ciapparelli A
Casten RJ. Review of Birren JE, Schaie KW (eds): *Handbook of the Psychology of Aging, 5th ed.* Feb 221
Cavazzoni PA see Carlson CD
Cecconi D see Ciapparelli A
Chakhava KO see Skurkovich SV
Chan AOM, Air TM, McFarlane AC. Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Feb 175–181
Chandra PS see Carey KB
Chang KD, Dienes K, Blasey C, Adleman N, Ketter T, Steiner H. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. Aug 936–942
Chang K-Y see Weinrieb RM
Chang L, Cloak CC, Ernst T. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. Suppl 3, 7–14
Chang W-H see Lane H-Y
Chang Y-C see Lane H-Y
Charuvastra VC see Shoptaw S
Chaudron LH, Pies RW. Relationship between postpartum psychosis and bipolar disorder: a review. Nov 1284–1292
Checkley SA see Kumar C
Chekhonin VP see Skurkovich SV
Chen C-C see Hong C-J
Chen J see Mallick R
Chen N see Davis JM
Cheng Y-C see Lane H-Y
Chengappa KNR. Introduction: using the newer pharmacotherapeutic agents as mood stabilizers in bipolar spectrum disorders. Suppl 8, 3–4
Chiavacci MC see Ciapparelli A
Chollet CAS, Andreatini R. Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality [letter]. Oct 1268–1269
Christensen RC. Olanzapine-associated bilateral pedal edema [letter]. Aug 972
Chrzanowski W see Fleischhacker WW
Chung H see Liebowitz MR
Chuong HW see Koran LM
Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Apr 451–458
Clarnette R see Brodaty H
Clary CM see Liebowitz MR
Cloak CC see Chang L
Cohane GH see Kanayama G
Cohen CI, Amassian VE, Akande B, Maccabee PJ. Efficacy and safety of bilateral rTMS in medication-resistant depression [letter]. May 613–614
Cohen IL see Tsiouris JA
Cohen LS. Gender-specific considerations in the treatment of mood disorders in women across the life cycle. Suppl 15, 18–29
Cohen LS see Soares CN; Stowe ZN
Cohen NL see Kennedy SH
Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Jan 60–62
Collins J see Strakowski SM
Colom F, Vieta E, Reinares M, Martínez-Arán A, Torrent C, Goikolea JM, Gastó C. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. Sept 1101–1105
Colom F see Vieta E

Colombo C see Benedetti F
Comes M see Vieta E
Conley R see Marder SR
Conley RR see Kelly DL
Corey KB see Strakowski SM
Corey-Lisle PK see Greenberg PE
Cormier JL see Winokur A
Correa J see Carvalhal AS
Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, Williamson DJ, Dubé S. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Nov 1349–1356
Cosenza A see Masi G
Cowen PJ see Sharpley AL
Cowley DS see Roy-Byrne PP
Crismon ML see Rush AJ; Suppes T
Croft HA see Labbate LA
Croghan TW see Cuffel BJ
Crowder MK. Review of Robinson DJ: *Brain Calipers, 2nd ed: Descriptive Psychopathology and the Psychiatric Mental Status Examination.* Apr 489–490
Csef H see Kraus MR
Cuffel BJ, Azocar F, Tomlin M, Greenfield SF, Busch AB, Croghan TW. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. Apr 397–402
Culpepper L. Fatigue and executive dysfunction in the primary care setting [commentary]. Suppl 14, 5
Culpepper L. Use of algorithms to treat anxiety in primary care. Suppl 2, 30–33
Culpepper L see Rodriguez BF
Cutlip WD II see Makela EH
Daldrup T see Müller-Vahl KR
Damatarca C see Stahl SM
Damsa C, Sterck R, Schulz P. Case of gynecomastia during paroxetine therapy [letter]. Aug 971
Daneman D see Findling RL
Daniel DG. Tolerability of ziprasidone: an expanding perspective. Suppl 19, 40–49
Datto CJ see Oslin DW
David D see Ginzburg K
Davies JT see Rapaport MH
Davies MA see Calabrese JR; Hirschfeld RMA
Davies T see Kumar C
Davis JM, Chen N. Choice of maintenance medication for schizophrenia. Suppl 16, 24–33
Davis JM see Janowsky DS
DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR, for the Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. Sept 1057–1064
de Graaf L, van Puijenbroek EP. Serotonin reuptake inhibitors and shocklike paresthesia [letter]. Aug 969–971
de Lissovoy G. Weighing the evidence: trends in managed care formulary decision making. Suppl 17, 29–32
Dell'Osso L see Ciapparelli A
DeMartinis NA III see Liebowitz MR; Winokur A
Denda K see Sasaki Y
de Nesnera A. Successful treatment with clozapine at higher doses after clozapine-induced priapism [letter]. Nov 1394–1395
Denicoff KD see Leverich GS; Post RM
Dennehy EB see Suppes T
Depakote Comparator Study Group see Revicki DA
DePaulo JR Jr see Mondimore FM
De Smedt G see Findling RL
Detke HC see Corya SA
Detke MJ. Reply to Fishbain DA: Analgesic effect of antidepressants [letter]. Jan 96–97
Detweiler MB, Trinkle DB. Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. July 851–852
Deus J see Cardoner N
DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. Suppl 18, 14–19
DeVeaugh-Geiss J see Calabrese JR
Dial E see Birnbaum HG
Dienes K see Chang KD
DiFilippo S see Oslin DW
Di Francesco L see Giaquinto S
Di Genio M see Troisi A
Dilsaver SC, Henderson-Fuller S, Akiskal HS. Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic. Oct 1170–1176
Docherty JP see Kane JM
Doghramji K. Treatment strategies for sleep disturbance in patients with depression. Suppl 14, 24–29
Doghramji K see DeBattista C
Donaldson S, Goldstein LH, Landau S, Raymont V, Frangou S. Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Jan 86–93
Donovan SJ, Nunes EV, Stewart JW, Ross D, Quitkin FM, Jensen PS, Klein DF. "Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? June 698–701
Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. Suppl 9, 11–17
Dotan I see Gothelf D
Douglas JE see Smith AG
Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. Suppl 15, 40–45
Draper BM see Brodaty H
Du J see Gray NA
Dubé S see Corya SA
Dunner DL. Drug interactions of lithium and other antimanic/mood-stabilizing medications. Suppl 5, 38–43
Dunner DL see Rapaport MH
Duval SE see Rothschild AJ
Earl N see Calabrese JR
Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, Fleischhacker WW. Olanzapine induces insulin resistance: results from a prospective study. Dec 1436–1439
Eder U see Ebenbichler CF; Hummer M
Eerdekens M see Fleischhacker WW
Eichhammer P, Johann M, Kharraz A, Binder H, Pittrow D, Wodarz N, Hajak G. High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. Aug 951–953
Ekstrom RD see Nicholas LM
Emrich HM see Müller-Vahl KR
Emsley RA see Oosthuizen PP
Ende G see Obergriesser T
Endicott J, McLaughlin TP, Grudzinski AN. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Dec 1511–1516
Entsuah AR see Mallick R
Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Suppl 16, 18–23
Ereshefsky L see Marder SR
Ernst T see Chang L
Eser D, Zwanzger P, Rupprecht R. Carbamazepine treatment of adverse psychiatric effects after treatment with the nonsteroidal anti-inflammatory drug piroxicam [letter]. July 852–854
Esposito SM see Nicholas LM
Etain B see Henry C
Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. Suppl 8, 9–14
Faller H see Kraus MR
Farabaugh AH see Papakostas GI
Faragian S see Poyurovsky M
Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? Suppl 11, 9–13
Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? Feb 123–133
Fava M. Depression with physical symptoms: treating to remission. Suppl 7, 24–28
Fava M. Role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. Suppl 13, 26–29
Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Suppl 14, 30–34
Fava M see Nierenberg AA; Papakostas GI
Fawcett JA. Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Suppl 5, 32–37
Fawcett J, Busch KA, Jacobs DG. Reply to Aldrich CK: Effectiveness of close watch precautions in suicidal patients [letter]. Dec 1520
Fawcett J, Busch KA, Jacobs DG. Reply to Rich CL: Treatment of anxiety in suicidal patients [letter]. Dec 1518–1519
Fawcett J see Busch KA
Fayek M see Simpson GM
Fayyad R see Liebowitz MR
Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JMA, Gibertini M. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. Mar 243–249

Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Sept 998–1004
Fenzi M see Ciapparelli A
Ferguson MB see Raskin J
Fieve RR see DeBattista C
Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. Nov 1362–1369
Fineberg NA, O'Doherty C, Rajagopal S, Reddy K, Banks A, Gale TM. How common is obsessive-compulsive disorder in a dermatology outpatient clinic? Feb 152–155
Fink M. Electroconvulsive therapy update: recognizing and treating psychotic depression [editorial]. Mar 232–234
Fischer M, Barkley RA. Childhood stimulant treatment and risk for later substance abuse. Suppl 11, 19–23
Fishbain DA. Analgesic effect of antidepressants [letter with reply]. Jan 96
Fitzgerald B see Cohen S
Fitzpatrick MJ. Advocacy perspective [commentary]. Suppl 17, 39–40
Fleck DE, Strakowski SM. Reply to Szarek BL: Racial differences in use of antipsychotics among patients with bipolar disorder [letter]. May 614–615
Fleck DE see Strakowski SM
Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P-M, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Oct 1250–1257
Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. Suppl 16, 10–13
Fleischhacker WW see Ebenbichler CF; Hummer M; Hofer A
Florita M see Benedetti F
Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. June 726–730
Ford AL see Nicholas LM
Ford S see Steiner H
Fowler RB see Lee DW
Frangou S see Donaldson S
Frank E see Miklowitz DJ
Freeman AM. Review of Shader RI (ed): *Manual of Psychiatric Therapeutics, 3rd ed.* Oct 1272
Freeman MP, Freeman SA. Treatment of leuprolide-induced depression with intramuscular testosterone: a case report [letter]. Mar 341–343
Freeman SA see Freeman MP
Freudenmann R see Kubesch S
Freudenreich O, Goff DC. Polypharmacy in schizophrenia: a fuzzy concept [letter with reply]. Sept 1132
Fried LP see Onder G
Friedberg J see Hollander E
Frisch A see Gothelf D
Frye MA see Calabrese JR; Hirschfeld RMA; Leverich GS; Post RM
Fuchs C see Poyurovsky M
Fujimoto KA see Reist C
Fukunaga T see Sakamoto K
Fuller GA see Mondimore FM
Gale TM see Fineberg NA
Gambassi G see Liperoti R
Gamel N see Aboujaoude E
Gary EM see Winokur A
Gary KA see Winokur A
Gastó C see Colom F
Gefvert O see Fleischhacker WW
Gelenberg AJ. Happy New Year! [editorial] Jan 8–11
Gemar M see Kennedy SH
Gentil V see Tavares H
George EL see Miklowitz DJ
Gergel I see Stahl SM
Gershon ES. Review of Gelder M, Mayou R, Cowen P: *Shorter Oxford Textbook of Psychiatry, 4th ed.* Jan 100–101
Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ. Oxcarbazepine treatment of bipolar disorder. Aug 943–945
Gianfrancesco FD. Reply to Lee DW: Olanzapine/risperidone and diabetes risk [letter]. July 848
Giaquinto S, Buzzelli S, Di Francesco L, Nolfe G. Evaluation of sexual changes after stroke. Mar 302–307
Gibel A see Ritsner M
Gibertini M see Feiger AD
Gibson PJ see Opolka JL
Gijsman HJ see Sharpley AL
Gillman PK. Amitriptyline: dual-action antidepressant? [letter with reply] Nov 1391–1392
Ginzburg K, Solomon Z, Koifman B, Keren G, Roth A, Kriwisky M, Kutz I, David D, Bleich A. Trajectories of posttraumatic stress disorder following myocardial infarction: a prospective study. Oct 1217–1223
Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Feb 119–122
Goethe JW see Szarek BL
Goff DC see Freudenreich O
Goikolea JM see Colom F; Vieta E
Golden RN see Nicholas LM
Goldman W. Health care organization perspective [commentary]. Suppl 17, 35–36
Goldsmith LJ see Godleski LS
Goldstein DJ see Raskin J
Goldstein LH see Donaldson S
Golshan S see Wetherell JL
González-Pinto A see Vieta E
Goodman M see Koenigsberg HW
Goodman WK see Hollander E
Goodwin FK. Impact of formularies on clinical innovation. Suppl 17, 11–14
Goodwin FK. Preventing inpatient suicide [COMMENTARY]. Jan 12–13
Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Suppl 5, 18–24
Gorali Y see Bonne O
Gorman JM. New molecular targets for antianxiety interventions. Suppl 3, 28–35
Gorman JM. Treating generalized anxiety disorder. Suppl 2, 24–29
Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, Inbar D, Steinberg T, Frisch A, Apter A, Weizman A. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Oct 1163–1169
Grady MM see Stahl SM
Gray NA, Zhou R, Du J, Moore GJ, Manji HK. Use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Suppl 5, 3–17
Greden JF. Physical symptoms of depression: unmet needs. Suppl 7, 5–11
Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. Economic burden of depression in the United States: how did it change between 1990 and 2000? Dec 1465–1475
Greenberg PE, Leong SA, Birnbaum HG, Robinson RL. Economic burden of depression with painful symptoms. Suppl 7, 17–23
Greenberg PE see Birnbaum HG
Greenfield SF see Cuffel BJ
Greist JH see Hollander E
Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. Suppl 5, 53–61
Groll C see Bottlender R
Grön G see Kubesch S
Grossberg GT. Diagnosis and treatment of Alzheimer's disease. Suppl 9, 3–6
Grossman F see Brodaty H
Gruber R see Gothelf D
Grudzinski AN see Endicott J
Grunze H, Langosch J, Born C, Schaub G, Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. July 781–784
Grunze H see Leverich GS
Gulanski B see Sernyak MJ
Gupta N see Relan P
Gupta S, Nienhaus K, Shah SA. Quetiapine and QTc issues: a case report [letter]. May 612–613
Guralnik JM see Onder G; Simeon D
Gutterman EM see Stahl SM
Haberfellner EM, Honsig T. Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics [letter]. July 851
Hafizi S see Sharpley AL
Hajak G see Eichhammer P
Hargrave R. Review of González FJ (ed): *HIV and Depression: Context and Care (UCSF AIDS Health Project Monograph Series, No. 5).* Feb 221–222
Harkavy-Friedman JM, Kimhy D, Nelson EA, Venarde DF, Malaspina D, Mann JJ. Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. Aug 871–874
Harrison WM see Russell JM

Hartong EGTM, Moleman P, Hoogduin CAL, Broekman TG, Nolen WA, and the LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Feb 144–151
Hartz AJ, Bentler SE, Brake KA, Kelly MW. Effectiveness of citalopram for idiopathic chronic fatigue. Aug 927–935
Harvey PD. Ziprasidone and cognition: the evolving story. Suppl 19, 33–39
Haynes D see Hendrick V
Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, Capece JA. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 2: improvement in psychiatric measures. Dec 1449–1454
Hedges DW see Hoopes SP
Heiser JF see Feiger AD
Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. May 575–579
Henderson-Fuller S see Dilsaver SC
Hendrick V, Smith LM, Hwang S, Altshuler LL, Haynes D. Weight gain in breastfed infants of mothers taking antidepressant medications. Apr 410–412
Henn FA see Obergriesser T
Hennen J see Baldessarini RJ
Henry C, Van den Bulke D, Bellivier F, Etain B, Rouillon F, Leboyer M. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Mar 331–335
Hensley PL see Nurnberg HG
Herz MI. Review of Lieberman JA, Murray R (eds): *Comprehensive Care of Schizophrenia: A Textbook of Clinical Management.* Apr 490
Hewett K see Stocchi F
Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. Sept 1025–1030
Hill A see Briken P
Hintikka J see Heiskanen T
Hirschfeld RMA. Efficacy of atypical antipsychotics in bipolar disorders. Suppl 8, 15–21
Hirschfeld RMA. Long-term side effects of SSRIs: sexual dysfunction and weight gain. Suppl 18, 20–24
Hirschfeld RMA, Baker JD, Wozniak P, Tracy K, Sommerville KW. Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. July 841–846
Hirschfeld RMA, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, Keck PE Jr, Lewis L, McElroy SL, McNulty JP, Wagner KD. Screening for bipolar disorder in the community. Jan 53–59
Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. Feb 161–174
Hirschfeld RMA see Calabrese JR; Russell JM
Hirschmann S see Ritsner M
Ho TP. Suicide risk of discharged psychiatric patients. June 702–707
Hodgins DC see Tavares H
Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient [letter]. Oct 1267–1268
Hofer A see Ebenbichler CF; Hummer M
Hollander E, for the Paroxetine OCD Study Group, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DR. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Sept 1113–1121
Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. May 546–550. Correction, Aug 972
Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM. Double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. June 640–647
Hollander E see Johnson SM
Hollander Y see Leung M
Holzmeister R see Hummer M
Hong C-J, Hu W-H, Chen C-C, Hsiao C-C, Tsai S-J, Ruwe FJL. Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Aug 921–926
Honsig T see Haberfellner EM
Hoogduin CAL see Hartong EGTM
Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, Capece JA, Karvois D. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 1: improvement in binge and purge measures. Nov 1335–1341
Hoopes SP see Hedges DW
Horn SD. Limiting access to psychiatric services can increase total health care costs. Suppl 17, 23–28
Hostetter AL see Stowe ZN
Hsiao C-C see Hong C-J
Hsieh Y-CM see Shoptaw S
Hsu DJ see Ghaemi SN
Hu W-H see Hong C-J
Hudson JI see McElroy SL
Hughes DH, Kleespies PM. Treating aggression in the psychiatric emergency service. Suppl 4, 10–15
Hummer M, Holzmeister R, Kemmler G, Eder U, Hofer A, Kurzthaler I, Oehl M, Weiss E, Fleischhacker WW. Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. Mar 277–281
Hummer M see Ebenbichler CF; Fleischhacker WW; Hofer A
Hwang S see Hendrick V
Hynan LS see Fontaine CS
Iacoviello BM see Nierenberg AA
Ibáñez A, Blanco C, Moreryra P, Sáiz-Ruiz J. Gender differences in pathological gambling. Mar 295–301
Inbar D see Gothelf D
Ingenito GG see Pigott TA
Inoue S see Sasaki Y
Inoue T see Sasaki Y
Isacsson G see Rich CL
Isometsä ET see Sokero TP
Ito S see Lee A
Iyengar MK see Stocchi F
Izumi Y see Terao T
Jacobs DG see Busch KA
Jacobs DG see Fawcett J
Jaffe AB, Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. Suppl 17, 3–6
Jäger M see Bottlender R
Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Oct 1258–1265
Jean-Baptiste M see Klein JP
Jefferson JW. They could have named it "bupopion" [letter]. July 849–850
Jefferson JW see Aga VM
Jenkins EA see Smith AG
Jensen PS see Donovan SJ
Jeste DV see Wetherell JL
Jiloha RC see Mendhekar DN
Johann M see Eichhammer P
Johnson SM, Hollander E. Evidence that eicosapentaenoic acid is effective in treating autism [letter]. July 848–849
Johnsrud MT see Opolka JL
Johnston I, Taylor PJ. Mental disorder and serious violence: the victims. July 819–824
Jokinen RH see Stocchi F
Jones H see Onder G
Joyce PR see Mulder RT
Kaiser CJ see Feldman PD
Kalin NH. Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems. Suppl 3, 41–44
Kamin M see Hedges DW; Hoopes SP
Kanayama G, Cohane GH, Weiss RD, Pope HG Jr. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? Feb 156–160
Kane JM. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management. Suppl 19, 3–5
Kane JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. Suppl 19, 19–25
Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Suppl 16, 34–40
Kane JM, Leucht S, Carpenter D, Docherty JP, eds. Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100
Kane JM see Carlson CD; Keith SJ; Marder SR
Kapczinski F see Carvalhal AS
Kaplan BJ see Simpson JSA
Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. Oct 1192–1194
Karcher K see Fleischhacker WW

Karim R see Hedges DW; Hoopes SP
Kartachov A see Oquendo MA
Karvois D see Hoopes SP
Kashner TM see Rush AJ; Suppes T
Katon WJ see Roy-Byrne PP; Vergouwen ACM
Katz IR see Oslin DW
Katz M see Bonne O
Kausch O. Suicide attempts among veterans seeking treatment for pathological gambling. Sept 1031–1038
Kawahara R see Maeda K
Kawashima T, Yamada S. Paroxetine-induced somnambulism [letter]. Apr 483
Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. Feb 215–216
Keck PE Jr, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. Dec 1426–1435
Keck PE Jr, McElroy SL. New approaches in managing bipolar depression. Suppl 1, 13–18
Keck PE Jr see Calabrese JR; Hirschfeld RMA; Leverich GS; McElroy SL; Post RM; Strakowski SM
Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. Nov 1308–1315
Keitner GA, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Sept 1091–1093
Keller MB see Russell JM; Rodriguez BF
Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Sept 1133–1134
Kelly KE see Nierenberg AA
Kelly LS see Corya SA
Kelly MW see Hartz AJ
Kemmler G see Ebenbichler CF; Hummer M; Weiss U
Kennedy JS see Feldman PD
Kennedy SH, Segal ZV, Cohen NL, Levitan RD, Gemar M, Bagby RM. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Apr 439–444
Keren G see Ginzburg K
Kessler RC see Greenberg PE
Ketter T see Chang KD
Ketter TA, Wang PW. Emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. Suppl 3, 15–20
Keyter N see Oosthuizen PP
Khait V see Oquendo MA
Khan A see Cohen S
Khan S see Cohen S
Kharraz A see Eichhammer P
Kilts CD. Potential new drug delivery systems for antidepressants: an overview. Suppl 18, 31–33
Kim M-D see Lavretsky H
Kimble R see Reeves RR
Kimhy D see Harkavy-Friedman JM
Kingsbury SJ see Simpson GM
Kintaudi PC see Shoptaw S
Kirshner HS. Review of Hodges JR (ed): *Early-Onset Dementia: A Multidisciplinary Approach.* Nov 1396
Kirwan J see Brodaty H
Klawe C see Szegedi A
Kleespies PM see Hughes DH
Klein DF see Donovan SJ
Klein JP, Jean-Baptiste M, Thompson JL, Bowers MB Jr. A case report of hypomania following vagus nerve stimulation for refractory epilepsy [letter]. Apr 485–486
Klinkman MS. Role of algorithms in the detection and treatment of depression in primary care. Suppl 2, 19–23
Klugman J see Ghaemi SN
Knutelska M see Simeon D
Koch K see Fontaine CS
Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ. Risperidone in the treatment of schizotypal personality disorder. June 628–634
Koerselman F see Vergouwen ACM
Koh KB. Reply to Benazzi F: Anger in bipolar depression [letter]. Apr 481
Kohnen R see Szegedi A
Koifman B see Ginzburg K
Kolbe H see Müller-Vahl KR
Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Suppl 11, 14–18
Komanduri R. Two cases of alcohol craving curbed by topiramate [letter]. May 612
Kopelowicz A, Lopez S. Review of The Committee on Cultural Psychiatry: *Cultural Assessment in Clinical Psychiatry (GAP Report 145).* Mar 344
Koposov R see Ruchkin V
Koran LM, Chuong HW, Bullock KD, Smith SC. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. July 793–798
Koran LM see Aboujaoude E; Hollander E
Kornstein SG see Russell JM
Korosh WM see Tsiouris JA
Koyama T see Sasaki Y
Kramer TAM. Review of Chan CH, Luo JS, Kennedy RS: *Concise Guide to Computers in Clinical Psychiatry.* Apr 487–488
Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. June 708–714
Krenz S see Zullino DF
Kreyenbuhl J see Kelly DL
Kriss V see Poyurovsky M
Kriwisky M see Ginzburg K
Kubesch S, Bretschneider V, Freudenmann R, Weidenhammer N, Lehmann M, Spitzer M, Grön G. Aerobic endurance exercise improves executive functions in depressed patients. Sept 1005–1012
Kuloglu M see Atmaca M
Kumar A see Lavretsky H
Kumar C, McIvor RJ, Davies T, Brown N, Papadopoulos A, Wieck A, Checkley SA, Campbell IC, Marks MN. Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Feb 112–118
Kunze I see Bottlender R
Kupka R see Leverich GS; Post RM
Kupka RW, Luckenbaugh DA, Post RM, Leverich GS, Nolen WA. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. Dec 1483–1494
Kurs R see Poyurovsky M; Ritsner M
Kurzthaler I see Hummer M
Kustermann S see Troisi A
Kusumakar V see Findling RL
Kutz I see Ginzburg K
Labbate LA, Croft HA, Oleshansky MA. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. Suppl 10, 11–19
Laimer M see Ebenbichler CF
Lam M see Lee A
Lamictal 605 Study Group see Calabrese JR
Landau S see Donaldson S
Langosch J see Grunze H
Lane H-Y, Chang Y-C, Cheng Y-C, Liu G-C, Lin X-R, Chang W-H. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Mar 316–320
Lapane KL see Liperoti R
Lara N, Baker GB, Archer SL, Le Mellédo J-M. Increased cholesterol levels during paroxetine administration in healthy men. Dec 1455–1459
Lavretsky H, Kim M-D, Kumar A, Reynolds CF III. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Dec 1410–1414
Leboyer M see Henry C
Lechleitner M see Ebenbichler CF
Lee A, Minhas R, Matsuda N, Lam M, Ito S. Safety of St. John's Wort (*Hypericum perforatum*) during breastfeeding. Aug 966–968
Lee DW, Fowler RB. Olanzapine/risperidone and diabetes risk [letter with reply]. July 847–848
Lee E see Brodaty H
Lee MA. Review of Csernansky JG (ed): *Schizophrenia: A New Guide for Clinicians.* Apr 489
Lehmann M see Kubesch S
Le Mellédo J-M see Lara N
Lenoci M see Neylan TC
Leo RJ. Word of caution about the implied role for duloxetine in pain management [letter]. Oct 1270
Leong SA see Greenberg PE
Lepola U, Arató M, Zhu Y, Austin C. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. June 654–662
Lepola UM see Stocchi F
Leskelä US see Sokero TP
Leslie D see Petrakis IL
Leslie DL see Sernyak MJ
Lestelä-Mielonen PS see Sokero TP
Leucht S see Kane JM
Leung M, Hollander Y, Brown GR. Pretreatment with ibuprofen to prevent electroconvulsive therapy–induced headache. May 551–553
Levenson JL. Burning mouth syndrome as a side effect of SSRIs [letter with reply]. Mar 336–337

Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Denicoff KD, Obrocea G, Nolen WA, Kupka R, Walden J, Grunze H, Perez S, Luckenbaugh DA, Post RM. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. May 506–515
Leverich GS see Kupka RW; Post RM
Levine J see Applebaum J; Jaffe AB
Levitan RD see Kennedy SH
Lewis JD see Weinrieb RM
Lewis L see Calabrese JR; Hirschfeld RMA
Lewis SJ see Godleski LS
Leykin Y see Neylan TC
Li D see Hollander E; Stahl SM
Libretto SE see Taylor DM
Lichtenberg FR. Economic and human impact of new drugs. Suppl 17, 15–18
Lie D see Brodaty H
Lieberman JA III. Differential diagnosis of fatigue and executive dysfunction in primary care. Suppl 14, 40–43
Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. July 785–792
Lin C-C see Bai Y-M
Lin X-R see Lane H-Y
Ling W see Shoptaw S
Lingg A see Weiss U
Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. Use of atypical antipsychotics in nursing homes. Sept 1106–1112
Liss TB see O'Keefe CD
LitCar Group see Hartong EGTM
Liu G-C see Lane H-Y
Liver O see Becker D
Llorca P-M see Fleischhacker WW
Lobo DSS see Tavares H
Lomax JW. Review of Paris J: *Personality Disorders Over Time: Precursors, Course, and Outcome.* Oct 1271
Londborg PD see Calabrese JR; Liebowitz MR
Lopez S see Kopelowicz A
López-Sala A see Cardoner N
Love RC see Kelly DL
Low L-F see Brodaty H
Lowe SW see Greenberg PE
Lu S see Phelan KM
Luckenbaugh DA see Kupka RW; Leverich GS; Post RM
Luty SE see Mulder RT
Lydiard RB. Role of GABA in anxiety disorders. Suppl 3, 21–27
Lynch KG see Weinrieb RM
Lyons B see Brodaty H
Lyytikäinen R see Heiskanen T
Maccabee PJ see Cohen CI
Machan JT see Rodriguez BF
Maeda K, Shirayama Y, Nukina S, Yoshioka S, Kawahara R. Charles Bonnet Syndrome with visual hallucinations of childhood experience: successful treatment of 1 patient with risperidone [letter]. Sept 1131–1132
Maglione ML see Neylan TC
Maharaj K see Privitera MR
Maina G, Bogetto F. Reply to Levenson JL: Burning mouth syndrome as a side effect of SSRIs [letter]. Mar 337–338
Makela EH, Miller K, Cutlip WD II. Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Apr 485–486
Malaspina D see Harkavy-Friedman JM
Malcolm RJ. GABA systems, benzodiazepines, and substance dependence. Suppl 3, 36–40
Malhotra S see McElroy SL
Mallett DA see Birnbaum HG
Mallick R, Chen J, Entsuah AR, Schatzberg AF. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mar 321–330
Mallinckrodt CH see Raskin J
Mangweth B see Ebenbichler CF
Manji HK see Gray NA
Mann JJ see Harkavy-Friedman JM; Oquendo MA
Manning JS. Difficult-to-treat depressions: a primary care perspective. Suppl 1, 24–31
Maples N see Velligan DI
Marcks BA see Twohig MP
Marder SR. Overview of partial compliance. Suppl 16, 3–9
Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. Clinical guidelines: dosing and switching strategies for long-acting risperidone. Suppl 16, 41–46
Marin H see Menza M; Rosen RC
Maritz JS see Oosthuizen PP
Markowitz JS see Stahl SM
Marks MN see Kumar C
Marksteiner J see Weiss U
Marmar CR see Neylan TC
Martí-Bonmatí E, Valero-Carcelén ES, Ortega-García MP, Rubini-Puig R. Olanzapine elevation of serum creatine kinase [letter]. Apr 483–484
Martin M see Mortimer AM
Martin S see Fleischhacker WW
Martin-Cook K see Fontaine CS
Martínez-Arán A see Colom F
Martins SS see Tavares H
Mascarenas CA see Ereshefsky L
Masi G, Cosenza A, Mucci M, Brovedani P. 3-Year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Sept 1039–1047
Mastin WD see Shale JH
Matsuda N see Lee A
Matsuyama T see Sasaki Y
Matthews AM. Review of Howlin P, Udwin O (eds): *Outcomes in Neurodevelopmental and Genetic Disorders.* Sept 1136
Matthews Z see Steiner H
Mattoo SK see Relan P
McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. Sept 984–989
McCullough JP see Russell JM
McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. Suppl 4, 16–25
McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. July 807–813
McElroy SL see Calabrese JR; Hirschfeld RMA; Keck PE Jr; Leverich GS; Post RM
McFarlane AC see Chan AOM
McIvor RJ see Kumar C
McKinney WT. Review of Kupfer DJ, First MB, Regier DA (eds): *A Research Agenda for DSM-IV.* Dec 1522
McLaughlin TP see Endicott J
McNally DP see Winokur A
McNulty JP see Calabrese JR; Hirschfeld RMA
Meador KJ. Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Suppl 8, 30–34
Mehtonen O-P see Calabrese JR
Melartin TK see Sokero TP
Menchón JM see Cardoner N
Mendhekar DN, Sharma JB, Srivastava PK, War L. Clozapine and pregnancy [letter]. July 850
Mendhekar DN, Srivastava PK, Sarin SK, Jiloha RC. Case report of olanzapine-induced fecal incontinence [letter]. Mar 339
Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptom-specific? May 516–523
Menza MA see DeBattista C
Mester R see Becker D; Spivak B
Metzler TJ see Neylan TC
Meyer JM. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C–seropositive state hospital patients: results from Oregon State Hospital. May 540–545
Miklowitz DJ, Richards JA, George EL, Frank E, Suddath RL, Powell KB, Sacher JA. Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Feb 182–191
Millar J see Brodaty H
Miller AL see Rush AJ; Suppes T; Velligan DI
Miller K see Makela EH
Miller MC. Review of Berrios GE, Hodges JR (eds): *Memory Disorders in Psychiatric Practice.* June 736–737
Minhas R see Lee A
Mintzer JE. Search for better noncholinergic treatment options for Alzheimer's disease. Suppl 9, 18–22
Mitchell JE see Roerig JL
Mitropoulou V see Koenigsberg HW
Modafinil in Depression Study Group see DeBattista C
Moleman P see Hartong EGTM
Möller H-J. Bipolar disorder and schizophrenia: distinct illnesses or a continuum? Suppl 6, 23–27
Möller H-J, Nasrallah HA. Treatment of bipolar disorder. Suppl 6, 9–17
Möller H-J see Bottlender R
Mondimore FM, Fuller GA, DePaulo JR Jr. Drug combinations for mania. Suppl 5, 25–31
Montealegre-Orjuela M see Smith AG
Montgomery JH, Tekell JL. Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report [letter]. Mar 339–341

Montgomery P see Calabrese JR
Moore GJ see Gray NA
Moore MC. Purchasing community perspective [commentary]. Suppl 17, 33–34
Mor V see Liperoti R
Moreryra P see Ibáñez A
Mortimer AM, Martin M, Wheeler Vega JA, Tyson PJ. Conventional antipsychotic prescription in unipolar depression, 2: withdrawing conventional antipsychotics in unipolar, nonpsychotic patients. June 668–672
Mortimer AM see Wheeler Vega JA
Moshang T see Findling RL
Mosholder AD see Phelan KM
Mrazek DA. Review of Ernst M, Rumsey JM (eds): *Functional Neuroimaging in Child Psychiatry*. Jan 102
Mucci M see Masi G
Mulder RT, Joyce PR, Luty SE. Relationship of personality disorders to treatment outcome in depressed outpatients. Mar 259–264
Müller MJ see Szegedi A
Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM. Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. Apr 459–465
Mundh H see Bourgeois JA
Murakami JL see Papakostas GI
Muscat E see Sahay N
Najjar F see Phillips KA
Nakamura J see Terao T
Nakamura K see Reist C
Nash JL. Review of Peebles-Kleiger MJ: *Beginnings: The Art and Science of Planning Psychotherapy*. June 736
Nasrallah HA see Möller H-J
Nejtek VA see Brown ES; Stewart RS
Nelson D see Simeon D
Nelson EA see Harkavy-Friedman JM
Nelson EB see McElroy SL
Nelson JC. Managing treatment-resistant major depression. Suppl 1, 5–12
Nemeroff CB. Anxiolytics: past, present, and future agents. Suppl 3, 3–6
Nemeroff CB. Improving antidepressant adherence. Suppl 18, 25–30
Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. May 532–539
Nemeroff CB see Stowe ZN
New AS see Koenigsberg HW
Neylan TC, Lenoci M, Maglione ML, Rosenlicht NZ, Leykin Y, Metzler TJ, Schoenfeld FB, Marmar CR. Effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. Apr 445–450
Neziroglu F see Yaryura-Tobias JA
Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. Effects of mirtazapine on plasma lipid profiles in healthy subjects. Aug 883–889
Nienhaus K see Gupta S
Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M. Nortriptyline for treatment-resistant depression. Jan 35–39
Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. Suppl 15, 13–17
Nierenberg AA see Papakostas GI
Ninan PT see Hollander E
Niskanen L see Heiskanen T
Nolan BP, Schulte JJ Jr. Mania associated with initiation of ziprasidone [letter]. Mar 336
Nolen WA see Hartong EGTM; Kupka RW; Leverich GS; Post RM
Nolfe G see Giaquinto S
Noordsy DL see O'Keefe CD
Nordera G see Stocchi F
Nukina S see Maeda K
Nunes EV see Donovan SJ
Nurnberg HG. Introduction. Erectile dysfunction and comorbid depression: prevalence, treatment strategies, and associated medical conditions. Suppl 10, 3–4
Nurnberg HG, Hensley PL. Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. Suppl 10, 20–25
Oakes R see Hollander E
Obergriesser T, Ende G, Braus DF, Henn FA. Long-term follow-up of magnetic resonance–detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy. July 775–780
Obrocea G see Leverich GS
O'Doherty C see Fineberg NA
Oehl M see Fleischhacker WW; Hummer M
Ohayon MM. Effects of breathing-related sleep disorders on mood disturbances in the general population. Oct 1195–1200
O'Keefe CD, Noordsy DL, Liss TB, Weiss H. Reversal of antipsychotic-associated weight gain. Aug 907–912
Okos A see Cohen S
Oleshansky MA see Labbate LA
Olivares JM see Vieta E
Onder G, Penninx BWJH, Guralnik JM, Jones H, Fried LP, Pahor M, Williamson JD. Sexual satisfaction and risk of disability in older women. Oct 1177–1182
Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. Sept 1075–1080
Opolka JL, Rascati KL, Brown CM, Barner JC, Johnsrud MT, Gibson PJ. Ethnic differences in use of antipsychotic medication among Texas Medicaid clients with schizophrenia. June 635–639
Opper RS see Menza M
Oquendo MA, Baca-Garcia E, Kartachov A, Khait V, Campbell CE, Richards M, Sackeim HA, Prudic J, Mann JJ. Computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. July 825–833
Orsulak PJ see Brown ES
Ortega-García MP see Martí-Bonmatí E
Oslin DW, Ten Have TR, Streim JE, Datto CJ, Weintraub D, DiFilippo S, Katz IR. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Aug 875–882
Oster EF see Birnbaum HG
O'Sullivan RL see Weiden PJ
Owens MJ see Stowe ZN
Pagano ME see Rodriguez BF
Pahor M see Onder G
Palmer BW see Wetherell JL
Papadopoulos A see Kumar C
Papadopoulos G see Stahl SM
Papakostas GI, Petersen TJ, Farabaugh AH, Murakami JL, Pava JA, Alpert JE, Fava M, Nierenberg AA. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Nov 1357–1361
Papakostas GI see Nierenberg AA
Paramore LC see Revicki DA
Parks JJ. Government perspective [commentary]. Suppl 17, 37–38
Paroxetine Generalized Anxiety Disorder Study Team see Stocchi F
Paroxetine OCD Study Group see Hollander E
Paska W see Calabrese JR
Paton C see Taylor DM
Paton H see Brodaty H
Patsch JR see Ebenbichler CF
Patterson TL see Wetherell JL
Patti PJ see Tsiouris JA
Pava JA see Papakostas GI
Pawliuk NH see Tempier RP
Pedone C see Liperoti R
Penninx BWJH see Onder G
Perantie DC see Brown ES
Percudani M, Barbui C. Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Nov 1293–1299
Perez S see Leverich GS
Pesce VC see Seidman SN
Petersen ML see Steiner H
Petersen T see Nierenberg AA
Petersen TJ see Nierenberg AA; Papakostas GI
Petrakis IL, Leslie D, Rosenheck R. Use of antidepressants in alcohol-dependent veterans. Aug 865–870
Pfab R see Brauer RB
Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Nov 1328–1334
Phillips KA, Najjar F. Open-label study of citalopram in body dysmorphic disorder. June 715–720
Pies RW see Chaudron LH
Pigott TA, Carson WH , Saha AR, Torbeyns AF, Stock EG, Ingenito GG, for the Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Sept 1048–1056
Pittrow D see Eichhammer P
Pitts CD see Rapaport MH
Poitras JR see Soares CN

Pollack MH see Doyle AC
Pollio C see Post RM
Pontiggia A see Benedetti F
Pope HG Jr see Kanayama G
Posey DJ see McDougle CJ
Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck PE Jr, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. June 680–690
Post RM see Kupka RW; Leverich GS
Posternak MA see Keitner GA
Potkin SG see Weiden PJ
Powell KB see Miklowitz DJ
Poyurovsky M, Kriss V, Weisman G, Faragian S, Kurs R, Schneidman M, Fuchs C, Weizman A, Weizman R. Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. Nov 1300–1307
Poyurovsky M, Kurs R, Weizman A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. May 611
Prakash R. Review of Barlow DH: *Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic, 2nd ed.* Mar 345–346
Presburger G see Gothelf D
Prevedel H see Müller-Vahl KR
Prihoda TJ see Velligan DI
Privitera MR, Maharaj K. Mania from dose-related ziprasidone augmentation of an SSRI [letter]. Nov 1393–1394
Prouty J see Soares CN
Prudic J see Oquendo MA
Pujol J see Cardoner N
Quitkin FM see Donovan SJ
Rabinowitz DC see Yaryura-Tobias JA
Rady A see Simpson GM
Rago WV see Rush AJ
Rajagopal S see Fineberg NA
Ramacciotti CE see Ciapparelli A
Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. Jan 20–29
Rao NR. Review of Arciniegas DB, Beresford TP: *Neuropsychiatry: An Introductory Approach.* May 616–617
Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. Sept 1065–1074
Rapoport M see Becker D
Rascati KL see Opolka JL
Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. Oct 1237–1244
Ratner Y see Ritsner M
Raymont V see Donaldson S
Reddy K see Fineberg NA
Reed M see Calabrese JR
Reed M see Hirschfeld RMA
Reeves RR, Kimble R. Prolonged erections associated with ziprasidone treatment: a case report [letter]. Jan 97–98
Regan WM. Review of Simon RI, Shuman DW (eds): *Retrospective Assessment of Mental States in Litigation: Predicting the Past.* Oct 1271–1272
Reimherr FW see Hedges DW; Hoopes SP
Reinares M see Colom F
Reist C, Nakamura K, Sagart E, Sokolski KN, Fujimoto KA. Impulsive aggressive behavior: open-label treatment with citalopram [letter]. Jan 81–85
Relan P, Gupta N, Mattoo SK. A case of risperidone-induced priapism [letter]. Apr 482–483
Remington G see Fleischhacker WW
Reus VI. Review of Rogers R: *Handbook of Diagnostic and Structured Interviewing.* Apr 488
Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM, for the Depakote Comparator Study Group. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Mar 288–294
Reynolds CF III see Lavretsky H
Reynolds D see Koenigsberg HW
Rich CL, Isacsson G. Treatment of anxiety in suicidal patients [letter with reply]. Dec 1518
Richards JA see Miklowitz DJ
Richards M see Oquendo MA
Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Suppl 13, 5–12
Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group see Taylor DM
Ritch JL see Velligan DI
Ritchie JC see Stowe ZN
Ritsner M. Attribution of somatization in schizophrenia patients: a naturalistic follow-up study. Nov 1370–1378
Ritsner M, Kurs R, Gibel A, Hirschmann S, Shinkarenko E, Ratner Y. Predictors of quality of life in major psychoses: a naturalistic follow-up study. Mar 308–315
Roback HB. Review of Yehuda R (ed): *Treating Trauma Survivors With PTSD.* May 617
Robinson RL see Greenberg PE
Rodriguez A see Vieta E
Rodriguez BF, Weisberg RB, Pagano ME, Machan JT, Culpepper L, Keller MB. Mental health treatment received by primary care patients with posttraumatic stress disorder. Oct 1230–1236
Roerig JL, Mitchell JE. Review of Marangell LB, Martinez JM, Silver JM, Yudofsky SC: *Concise Guide to Psychopharmacology.* Nov 1397–1398
Ronis RJ. Review of Hofmann SG, Tompson MC (eds): *Treating Chronic and Severe Mental Disorders: A Handbook of Empirically Supported Interventions.* Dec 1524
Roose SP. Depression: links with ischemic heart disease and erectile dysfunction. Suppl 10, 26–30
Roose SP see Seidman SN
Rosen RC, Marin H. Prevalence of antidepressant-associated erectile dysfunction. Suppl 10, 5–10
Rosenheck R see Petrakis IL; Sernyak MJ
Rosenlicht NZ see Neylan TC
Rosenquist KJ see Ghaemi SN
Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Oct 1245–1249
Rosenthal MH see DeBattista C
Rosenthal NR see Hedges DW; Hoopes SP
Ross D see Donovan SJ
Roth A see Ginzburg K
Rotheram-Fuller EJ see Shoptaw S
Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? Apr 390–396
Rouillon F see Henry C
Roy-Byrne PP, Russo J, Cowley DS, Katon WJ. Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Apr 383–389
Rubini-Puig R see Martí-Bonmatí E
Ruchkin V, Koposov R, Vermeiren R, Schwab-Stone M. Psychopathology and age at onset of conduct problems in juvenile delinquents. Aug 913–920
Rupprecht R see Eser D
Rush AJ. Conclusions. Bipolar disorder: origin, recognition, and treatment. Suppl 6, 28
Rush AJ. Introduction. Bipolar disorder: origin, recognition, and treatment. Suppl 6, 3
Rush AJ. Toward an understanding of bipolar disorder and its origin. Suppl 6, 4–8
Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K, Witte BP, Shon SP, Rago WV, Altshuler KZ, for the TMAP Research Group. Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Apr 357–369
Rush AJ see Post RM; Sachs GS; Suppes T
Russell JM, Kornstein SG, Shea MT, McCullough JP, Harrison WM, Hirschfeld RMA, Keller MB. Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. May 554–561
Russo J see Roy-Byrne PP
Ruwe FJL see Hong C-J
Ryabukhin IA see Skurkovich SV
Ryan CE see Keitner GA
Rytsälä HJ see Sokero TP
Saarinen PI see Heiskanen T
Sacher JA see Miklowitz DJ
Sachs GS. Decision tree for the treatment of bipolar disorder. Suppl 8, 35–40
Sachs GS, Rush AJ. Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals? Suppl 6, 18–22
Sachs GS see Calabrese JR; Yildiz A
Sackeim HA see Oquendo MA
Sagart E see Reist C
Sagduyu K. Hydroxyzine for generalized anxiety disorder [letter]. Mar 343
Saha AR see Pigott TA
Sahay N, Muscat E, Bowers MB Jr. Possible antidepressant-associated activation of mania and psychosis in the mentally retarded: four case reports [letter]. Apr 481–482
Sáiz-Ruiz J see Ibáñez A
Sakamoto K, Fukunaga T. Impact of attempted suicide on the symptoms and course of mood disorders. Oct 1210–1216

Salomon RM. Review of Helzer JE, Hudziak JJ (eds): *Defining Psychopathology in the 21st Century: DSM-V and Beyond.* Nov 1399
Salomon RM. Review of Kaplan GB, Hammer RP Jr (eds): *Brain Circuitry and Signaling in Psychiatry: Basic Science and Clinical Implications.* June 737
Salomon RM see Hewlett WA
Salzman C. Review of Stahl SM: *Essential Psychopharmacology of Antipsychotics and Mood Stabilizers.* Aug 973–974
Sánchez-Moreno J see Vieta E
Sanger TM see Corya SA
Sano M. Noncholinergic treatment options for Alzheimer's disease. Suppl 9, 23–28
Sarin SK see Mendhekar DN
Sartorius N. Physical symptoms of depression as a public health concern. Suppl 7, 3–4
Sasaki Y, Matsuyama T, Inoue S, Sunami T, Inoue T, Denda K, Koyama T. Prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Nov 1316–1321
Sato T see Bottlender R
Sattar SP, Bhatia SC. Olanzapine for cocaine cravings and relapse prevention [letter]. Aug 969
Saxena K see Steiner H
Schäfer A see Kraus MR
Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Suppl 13, 30–37
Schatzberg AF. Introduction: recent developments in achieving depression remission. Suppl 13, 4
Schatzberg AF. Introduction: treating depression and anxiety to remission. Suppl 15, 3–4
Schatzberg AF. New approaches to managing psychotic depression. Suppl 1, 19–23
Schatzberg AF see Mallick R
Schaub G see Grunze H
Scheurlen M see Kraus MR
Schmid SP see Hewlett WA
Schnaas FJ. Review of Gotlib IH, Hammen CL (eds): *Handbook of Depression.* Dec 1523–1524
Schneider LS see Rapaport MH
Schneider U see Müller-Vahl KR
Schneidman M see Poyurovsky M
Schoenfeld FB see Neylan TC
Schooler NR. Maintaining symptom control: review of ziprasidone long-term efficacy data. Suppl 19, 26–32
Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. Suppl 16, 14–17
Schulte JJ Jr see Nolan BP
Schulz P see Damsa C
Schwab-Stone M see Ruchkin V
Segal KR see Aronne LJ
Segal ZV see Kennedy SH
Seidman SN. Aging male: androgens, erectile dysfunction, and depression. Suppl 10, 31–37
Seidman SN, Pesce VC, Roose SP. High-dose sildenafil citrate for selective serotonin reuptake inhibitor–associated ejaculatory delay: open clinical trial. June 721–725
Selten J-P, Büller H. Clozapine and venous thromboembolism: further evidence [letter]. May 609
Sernyak MJ, Gulanski B, Leslie DL, Rosenheck R. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. May 605–608
Sethi S, Bhargava SC. Clozapine-induced rabbit syndrome [letter]. Feb 219
Sexson SB. Review of Martin A, Scahill L, Charney DS, Leckman JF (eds): *Pediatric Psychopharmacology: Principles and Practice.* Aug 974
Shabash E see Spivak B
Shah N see Andrade C
Shah SA see Gupta S
Shale CM see Shale JH
Shale JH, Shale CM, Mastin WD. Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. May 500–505
Shalev AY see Bonne O
Sharah S see Brodaty H
Sharma JB see Mendhekar DN
Sharma V. Agitation and inpatient suicide [letter with reply]. Dec 1517–1518
Sharpley AL, Bhagwagar Z, Hafizi S, Whale WR, Gijsman HJ, Cowen PJ. Risperidonę augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Feb 192–196
Shayegan DK see Stahl SM
Shea MT see Russell JM
Sheitman B see Spivak B
Shelton MD see Calabrese JR
Shelton RC. Use of antidepressants in novel combination therapies. Suppl 2, 14–18
Shifren JL see Soares CN
Shemer Y see Bonne O
Sheshai AE see Simpson GM
Shi L see Birnbaum HG
Shimomura T see Terao T
Shinkarenko E see Ritsner M
Shirayama Y see Maeda K
Shon SP see Rush AJ; Suppes T
Shoptaw S, Yang X, Rotheram-Fuller EJ, Hsieh Y-CM, Kintaudi PC, Charuvastra VC, Ling W. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. Dec 1440–1448
Shores-Wilson K see Rush AJ; Suppes T
Shrivastava RK see Feiger AD
Siever LJ see Koenigsberg HW
Siewert JR see Brauer RB
Silk KR, Yager J. Suggested guidelines for e-mail communication in psychiatric practice. July 799–806
Silveira CM see Tavares H
Silverman J see Koenigsberg HW
Simeon D, Knutelska M, Nelson D, Guralnik O. Feeling unreal: a depersonalization disorder update of 117 cases. Sept 990–997
Simmons M. Nutritional approach to bipolar disorder [letter with reply]. Mar 338
Simpson GM, Sheshai AE, Rady A, Kingsbury SJ, Fayek M. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. Aug 959–965
Simpson GM see Weiden PJ
Simpson JSA, Kaplan BJ. Reply to Simmons M: Nutritional approach to bipolar disorder [letter]. Mar 338–339
Siracusano A see Troisi A
Siris SG, Siris Nash S. Review of Herz MI, Marder SR: *Schizophrenia: Comprehensive Treatment and Management.* Mar 345
Siris Nash S see Siris SG
Sitsen JMA see Feiger AD
Skurkovich B see Skurkovich SV
Skurkovich SV, Aleksandrovsky YA, Chekhonin VP, Ryabukhin IA, Chakhava KO, Skurkovich B. Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor-α and to interferon-γ: a case report [letter]. June 734–735
Slomowitz M. Review of Mondimore FM: *Adolescent Depression: A Guide for Parents.* July 855
Smeraldi E see Benedetti F
Smith AG, Montealegre-Orjuela M, Douglas JE, Jenkins EA. Venlafaxine for pathological crying after stroke [letter]. June 731–732
Smith SC see Koran LM
Smith LM see Hendrick V
Smith WT see Feiger AD; Liebowitz MR
Snaterse M see Welch R
Snowdon J. Reporting changes in scores on the Cohen-Mansfield Agitation Inventory subscales [letter with reply]. June 732
Snowdon J see Brodaty H
Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL, Cohen LS. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Apr 473–479
Sokero TP, Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Isometsä ET. Suicidal ideation and attempts among psychiatric patients with major depressive disorder. Sept 1094–1100
Sokolski KN see Reist C
Solomon Z see Ginzburg K
Sommerville KW see Hirschfeld RMA; Revicki DA
Soumerai S. Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill. Suppl 17, 19–22
Spitzer M see Kubesch S
Spivak B, Shabash E, Sheitman B, Weizman A, Mester R. Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. July 755–760
Spode A see Carvalhal AS
Srivastava PK see Mendhekar DN
Stahl SM. Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes [BRAINSTORMS]. July 745–746
Stahl SM. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies [BRAINSTORMS]. Apr 355–356
Stahl SM. Deconstructing psychiatric disorders, pt 1: genotypes, symptom phenotypes, and endophenotypes [BRAINSTORMS]. Sept 982–983

Stahl SM. Deconstructing psychiatric disorders, pt 2: an emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist [Brainstorms]. Oct 1145–1146
Stahl SM. Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes [Brainstorms]. Aug 863–864
Stahl SM. Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction. Suppl 14, 3–4
Stahl SM. Neurotransmission of cognition, pt 1: dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine [Brainstorms]. Jan 4–5
Stahl SM. Neurotransmission of cognition, pt 2: selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition [Brainstorms]. Feb 110–111
Stahl SM. Neurotransmission of cognition, pt 3: mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex [Brainstorms]. Mar 230–231
Stahl SM. Reply to Freudenreich O: Polypharmacy in schizophrenia: a fuzzy concept [letter]. Sept 1132–1133
Stahl SM. Reply to Welch R: Combination therapy: is clinical practice leading the way? [letter] Jan 94–96
Stahl SM. Symptoms and circuits, pt 1: major depressive disorder [Brainstorms]. Nov 1282–1283
Stahl SM. Symptoms and circuits, pt 2: anxiety disorders [Brainstorms]. Dec 1408–1409
Stahl SM. Ups and downs of novel antiemetic drugs, pt 1: substance P, 5-HT, and the neuropharmacology of vomiting [Brainstorms]. May 498–499
Stahl SM. Ups and downs of novel antiemetic drugs, pt 2: an illustration [Brainstorms]. June 626–627
Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Nov 1322–1327
Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. Suppl 13, 13–17
Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Apr 466–472
Stahl SM, Shayegan DK. Psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Suppl 19, 6–12
Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Suppl 14, 6–17
Stangl M see Brauer RB
Stein MB. Attending to anxiety disorders in primary care. Suppl 15, 35–39
Steinberg T see Gothelf D
Steiner H, Petersen ML, Saxena K, Ford S, Matthews Z. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. Oct 1183–1191
Steiner H see Chang KD
Steiner M see Hollander E
Sterck R see Damsa C
Sternbach H. Are antidepressants carcinogenic? a review of preclinical and clinical studies. Oct 1153–1162
Sternberg K see Stowe ZN
Stewart DE. Physical symptoms of depression: unmet needs in special populations. Suppl 7, 12–16
Stewart JW see Donovan SJ
Stewart RS, Nejtek VA. Open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. Jan 49–52
Stigler KA see McDougle CJ
Stikovac DM see Godleski LS
Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK, for the Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Mar 250–258
Stock EG see Pigott TA
Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS, Nemeroff CB. Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Jan 73–80
Strain JJ. Review of Bennett MI: *Concise Guide to Managing Behavioral Health Care Within a Managed Care Environment.* Nov 1398
Strakowski SM, Keck PE Jr, Arnold LM, Collins J, Wilson RM, Fleck DE, Corey KB, Amicone J, Adebimpe VR. Ethnicity and diagnosis in patients with affective disorders. July 747–754
Strakowski SM see Fleck DE
Straumanis J. Review of Hollander E: *Concise Guide to Anxiety Disorders.* Nov 1396–1397
Straumanis JJ. Review of Töres Theorell (ed): *Everyday Biological Stress Mechanisms.* Mar 344–345
Strauss GD. Review of Melmed RN: *Mind, Body, and Medicine: An Integrative Text.* Jan 101–102
Streim JE see Oslin DW
Sudak HS. Review of Phillips KA (ed): *Somatoform and Factitious Disorders.* Jan 99–100
Suddath RL see Miklowitz DJ
Sui D see Velligan DI
Sunami T see Sasaki Y
Suppes T, Rush AJ, Dennehy EB, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Brown ES, Biggs MM, Shores-Wilson K, Witte BP, Trivedi MH, Miller AL, Altshuler KZ, Shon SP. Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Apr 370–382
Suppes T see Leverich GS; Rush AJ
Suppes TM see Post RM
Sutton VK see Feldman PD
Svetlik D see Fontaine CS
Swann AC. Neuroreceptor mechanisms of aggression and its treatment. Suppl 4, 26–35
Swann AC see Revicki DA
Swanson JM. Role of executive function in ADHD. Suppl 14, 35–39
Szarek BL, Goethe JW. Racial differences in use of antipsychotics among patients with bipolar disorder [letter with reply]. May 614–615
Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Apr 413–420
Takeshita J. Internet pharmacy prescription and phentermine overdose. Feb 215
Tamminga CA. Similarities and differences among antipsychotics. Suppl 17, 7–10
Tavares H, Martins SS, Lobo DSS, Silveira CM, Gentil V, Hodgins DC. Factors at play in faster progression for female pathological gamblers: an exploratory analysis. Apr 433–438
Taylor DM, Wright T, Libretto SE, for the Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. May 589–597
Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Jan 30–34
Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. Dec 1421–1425
Taylor PJ see Johnston I
Tedlow J see Nierenberg AA
Tekell JL see Montgomery JH
Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. June 673–679
Ten Have TR see Oslin DW
Teng EJ see Twohig MP
Terao T, Shimomura T, Izumi Y, Nakamura J. Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Dec 1520–1521
Terao T, Shimomura T, Nakamura J. Can donepezil be considered a mild antipsychotic in dementia treatment? a report of donepezil use in 6 patients [letter]. Nov 1392–1393
Texas Medication Algorithm Project Research Group see Rush AJ
Tezcan E see Atmaca M
Tharyan P see Andrade C
Thase ME. Achieving remission and managing relapse in depression. Suppl 18, 3–7
Thase ME. Effectiveness of antidepressants: comparative remission rates. Suppl 2, 3–7
Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. Suppl 13, 18–25
Thase ME. New approaches to managing difficult-to-treat depressions. Suppl 1, 3–4
Thase ME. Reply to Gillman PK: Amitriptyline: dual-action antidepressant? [letter] Nov 1391–1392
Thase ME see Calabrese JR
Theloe K see Müller-Vahl KR
Thompson JL see Klein JP
Thorp SR see Wetherell JL
Tollefson GD see Feldman PD
Tomarken AJ see Brown LL
Tomlin M see Cuffel BJ

Tondo L see Baldessarini RJ
Toprac MG see Rush AJ; Suppes T
Torbeyns AF see Pigott TA
Torrent C see Colom F; Vieta E
Tracy K see Hirschfeld RMA
Tran PV see Feldman PD
Trestman RL see Koenigsberg HW
Trinkle DB see Detweiler MB
Trivedi MH. Using treatment algorithms to bring patients to remission. Suppl 2, 8–13
Trivedi MH see Rush AJ; Suppes T
Troisi A, Kustermann S, Di Genio M, Siracusano A. Hostility during admission interview as a short-term predictor of aggression in acute psychiatric male inpatients. Dec 1460–1464
Tsai S-J see Hong C-J
Tsiouris JA, Cohen IL, Patti PJ, Korosh WM. Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. Sept 1081–1090
Turner JA see Oosthuizen PP
Turner MS see Marder SR
Twohig MP, Woods DW, Marcks BA, Teng EJ. Evaluating the efficacy of habit reversal: comparison with a placebo control. Jan 40–48
Tyson PJ see Mortimer AM; Wheeler Vega JA
Urcuyo L see McCue RE
Urretavizcaya M see Cardoner N
Ustundag B see Atmaca M
Vaillant GE. Review of Horowitz MJ: *Treatment of Stress Response Syndromes.* Oct 1272–1273
Valero-Carcelén ES see Martí-Bonmatí E
Vallejo J see Cardoner N
Van Campen LE see Corya SA
Van den Bulke D see Henry C
Van-Duong Q see Kelly DL
van Puijenbroek EP see de Graaf L
Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. May 524–531
Venarde DF see Harkavy-Friedman JM
Vergouwen ACM, Bakker A, Katon WJ, Verheij TJ, Koerselman F. Improving adherence to antidepressants: a systematic review of interventions. Dec 1415–1420
Verheij TJ see Vergouwen ACM
Vermeiren R see Ruchkin V
Vermetten E, Bremner JD. Olfaction as a traumatic reminder in posttraumatic stress disorder: case reports and review. Feb 202–207
Vieta E. Divalproex versus olanzapine in mania [letter with reply]. Oct 1266
Vieta E, Goikolea JM, Olivares JM, González-Pinto A, Rodriguez A, Colom F, Comes M, Torrent C, Sánchez-Moreno J. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. July 834–839
Vieta E see Colom F
Vieweg WV see Godleski LS
Vonbank H see Weiss U
Vornik LA Hirschfeld RMA
Vorster M see Barbosa L
Wagner KD see Calabrese JR; Hirschfeld RMA
Waheed R see McCue RE
Wahid ZU. Review of Jacobson SA, Pies RW, Greenblatt DJ: *Handbook of Geriatric Psychopharmacology.* Jan 101
Walden J see Grunze H; Leverich GS
Wang PW see Ketter TA
War L see Mendhekar DN
Wasserman S see Hollander E
Wei H see Carlson CD
Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. May 580–588
Weidenhammer N see Kubesch S
Weihs K see Liebowitz MR
Weiner MF see Fontaine CS
Weinrieb RM, Auriacombe M, Lynch KG, Chang K-Y, Lewis JD. Critical review of selective serotonin reuptake inhibitor–associated bleeding: balancing the risk of treating hepatitis C–infected patients. Dec 1502–1510
Weintraub D see Oslin DW
Weisberg RB see Rodriguez BF
Weisman G see Poyurovsky M
Weiss E see Ebenbichler CF; Hummer M
Weiss H see O'Keefe CD
Weiss KJ see Feiger AD
Weiss M see Becker D
Weiss RD see Kanayama G
Weiss U, Bacher R, Vonbank H, Kemmler G, Lingg A, Marksteiner J. Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. Mar 235–242
Weissman MM see Hirschfeld RMA
Weissman SH. Review of Scheiber SC, Kramer TAM, Adamowski SE (eds): *Core Competencies for Psychiatric Practice: What Clinicians Need to Know (A Report of the American Board of Psychiatry and Neurology).* Sept 1135
Weizman A see Becker D; Gothelf D; Poyurovsky M; Spivak B
Weizman R see Poyurovsky M
Welch R, Snaterse M. Combination therapy: is clinical practice leading the way? [letter with reply] Jan 94
Welge JA see McElroy SL
Wenk GL. Neuropathologic changes in Alzheimer's disease. Suppl 9, 7–10
Wetherell JL, Palmer BW, Thorp SR, Patterson TL, Golshan S, Jeste DV. Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Dec 1476–1482
Whale WR see Sharpley AL
Wheadon DE see Hollander E
Wheeler Vega JA, Mortimer AM, Tyson PJ. Conventional antipsychotic prescription in unipolar depression, 1: an audit and recommendations for practice. May 568–574
Wheeler Vega JA see Mortimer AM
White HS. Mechanism of action of newer anticonvulsants. Suppl 8, 5–8
Wieck A see Kumar C
Wilens T see Faraone SV
Williamson DJ see Corya SA
Williamson JD see Onder G
Wilson RM see Strakowski SM
Winokur A, DeMartinis NA III, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Oct 1224–1229
Witte BP see Rush AJ; Suppes T
Wodarz N see Eichhammer P
Woods DW see Twohig MP
Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. June 663–667
Woodward M see Brodaty H
Worthington JJ see Nierenberg AA
Wozniak P see Hirschfeld RMA
Wright T see Taylor DM
Yager J see Silk KR
Yamada S see Kawashima T
Yang H see Hollander E
Yang X see Shoptaw S
Yaryura-Tobias JA, Rabinowitz DC, Neziroglu F. Possible basal ganglia pathology in children with complex symptoms. Dec 1495–1501
Yatham LN see Calabrese JR
Yildiz A, Sachs GS. Do antidepressants induce rapid cycling? a gender-specific association. July 814–818
Yonkers KA. Special issues related to the treatment of depression in women. Suppl 18, 8–13
Yoshioka S see Maeda K
Young C see Taylor DM
Yu S-C see Bai Y-M
Zajecka JM. Reply to Vieta E: Divalproex versus olanzapine in mania [letter]. Oct 1266–1267
Zajecka JM. Treating depression to remission. Suppl 15, 7–12
Zajecka JM see Revicki DA
Zettwoch NC see Godleski LS
Zhang F see Feldman PD
Zhang L see Stahl SM
Zhou R see Gray NA
Zhu Y see Lepola U
Zullino DF, Krenz S, Besson J. AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD [letter]. Feb 219–220
Zwanzger P see Eser D